TWI784840B - 用於治療或預防與β-3腎上腺素受體相關病症之β-3腎上腺素受體調節劑 - Google Patents
用於治療或預防與β-3腎上腺素受體相關病症之β-3腎上腺素受體調節劑 Download PDFInfo
- Publication number
- TWI784840B TWI784840B TW110147004A TW110147004A TWI784840B TW I784840 B TWI784840 B TW I784840B TW 110147004 A TW110147004 A TW 110147004A TW 110147004 A TW110147004 A TW 110147004A TW I784840 B TWI784840 B TW I784840B
- Authority
- TW
- Taiwan
- Prior art keywords
- oxa
- azaspiro
- phenoxy
- dec
- ylsulfonyl
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract description 32
- 108010014502 beta-3 Adrenergic Receptors Proteins 0.000 title abstract description 29
- 102000016959 beta-3 Adrenergic Receptors Human genes 0.000 title abstract description 8
- 230000002265 prevention Effects 0.000 title description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 380
- 206010019280 Heart failures Diseases 0.000 claims abstract description 76
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 57
- -1 1-oxa-8-azaspiro[4.5]dec-8-ylsulfonyl Chemical group 0.000 claims description 1153
- 238000002360 preparation method Methods 0.000 claims description 197
- 239000003814 drug Substances 0.000 claims description 27
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 23
- PMZDQRJGMBOQBF-UHFFFAOYSA-N quinolin-4-ol Chemical compound C1=CC=C2C(O)=CC=NC2=C1 PMZDQRJGMBOQBF-UHFFFAOYSA-N 0.000 claims description 19
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 9
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 8
- XWQVQSXLXAXOPJ-QNGMFEMESA-N 4-[[[6-[5-chloro-2-[[4-[[(2r)-1-methoxypropan-2-yl]amino]cyclohexyl]amino]pyridin-4-yl]pyridin-2-yl]amino]methyl]oxane-4-carbonitrile Chemical compound C1CC(N[C@H](C)COC)CCC1NC1=CC(C=2N=C(NCC3(CCOCC3)C#N)C=CC=2)=C(Cl)C=N1 XWQVQSXLXAXOPJ-QNGMFEMESA-N 0.000 claims description 5
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 6
- YKGMKSIHIVVYKY-UHFFFAOYSA-N dabrafenib mesylate Chemical compound CS(O)(=O)=O.S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 YKGMKSIHIVVYKY-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 120
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 67
- 208000035475 disorder Diseases 0.000 abstract description 52
- 230000001404 mediated effect Effects 0.000 abstract description 52
- 210000002216 heart Anatomy 0.000 abstract description 33
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 abstract description 17
- 206010007556 Cardiac failure acute Diseases 0.000 abstract description 16
- 230000002861 ventricular Effects 0.000 abstract description 13
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract description 12
- 206010024119 Left ventricular failure Diseases 0.000 abstract description 12
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 12
- 208000010125 myocardial infarction Diseases 0.000 abstract description 12
- 238000002583 angiography Methods 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 9
- 230000000747 cardiac effect Effects 0.000 abstract description 8
- 206010067125 Liver injury Diseases 0.000 abstract description 6
- 230000006378 damage Effects 0.000 abstract description 6
- 238000002592 echocardiography Methods 0.000 abstract description 6
- 210000003709 heart valve Anatomy 0.000 abstract description 6
- 231100000234 hepatic damage Toxicity 0.000 abstract description 6
- 210000003734 kidney Anatomy 0.000 abstract description 6
- 230000008818 liver damage Effects 0.000 abstract description 6
- 230000008816 organ damage Effects 0.000 abstract description 6
- 230000033764 rhythmic process Effects 0.000 abstract description 6
- PCBOWMZAEDDKNH-HOTGVXAUSA-N [4-(trifluoromethoxy)phenyl]methyl (3as,6as)-2-(3-fluoro-4-sulfamoylbenzoyl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-5-carboxylate Chemical compound C1=C(F)C(S(=O)(=O)N)=CC=C1C(=O)N1C[C@H]2CN(C(=O)OCC=3C=CC(OC(F)(F)F)=CC=3)C[C@@H]2C1 PCBOWMZAEDDKNH-HOTGVXAUSA-N 0.000 description 175
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 174
- 238000006243 chemical reaction Methods 0.000 description 154
- 239000000203 mixture Substances 0.000 description 151
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 150
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 135
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 131
- UMXZEBRLWAEPPM-UHFFFAOYSA-N 7-benzylsulfanyl-1-(2-methoxyethyl)-2,3-dihydropyrido[2,3-b][1,4]oxazine Chemical compound C(C1=CC=CC=C1)SC1=CC2=C(OCCN2CCOC)N=C1 UMXZEBRLWAEPPM-UHFFFAOYSA-N 0.000 description 129
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 124
- 239000000243 solution Substances 0.000 description 112
- 238000005160 1H NMR spectroscopy Methods 0.000 description 108
- 239000002585 base Substances 0.000 description 100
- 239000007787 solid Substances 0.000 description 82
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 71
- 239000012267 brine Substances 0.000 description 69
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 69
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 66
- 125000001424 substituent group Chemical group 0.000 description 66
- 239000011734 sodium Substances 0.000 description 63
- 238000010898 silica gel chromatography Methods 0.000 description 60
- 235000019439 ethyl acetate Nutrition 0.000 description 58
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 55
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 52
- 239000011541 reaction mixture Substances 0.000 description 47
- 150000003839 salts Chemical class 0.000 description 46
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 44
- 125000004076 pyridyl group Chemical group 0.000 description 44
- 239000000460 chlorine Substances 0.000 description 43
- IUUZMZHMHDVICT-SECBINFHSA-N (2S)-2-[(3-methylsulfonylphenoxy)methyl]oxirane Chemical compound CS(=O)(=O)C=1C=C(OC[C@H]2OC2)C=CC=1 IUUZMZHMHDVICT-SECBINFHSA-N 0.000 description 42
- 102000012367 Beta 3 adrenoceptor Human genes 0.000 description 42
- 108040005346 beta3-adrenergic receptor activity proteins Proteins 0.000 description 42
- 239000012044 organic layer Substances 0.000 description 42
- 239000012141 concentrate Substances 0.000 description 41
- 235000008504 concentrate Nutrition 0.000 description 41
- 239000000706 filtrate Substances 0.000 description 39
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 38
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 36
- 239000010410 layer Substances 0.000 description 36
- 238000000746 purification Methods 0.000 description 34
- 239000012453 solvate Substances 0.000 description 34
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 33
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 32
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 32
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 32
- 229910052736 halogen Inorganic materials 0.000 description 31
- 150000002367 halogens Chemical class 0.000 description 31
- 150000004677 hydrates Chemical class 0.000 description 31
- 229910052799 carbon Inorganic materials 0.000 description 29
- 239000000725 suspension Substances 0.000 description 28
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 27
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 26
- 239000007864 aqueous solution Substances 0.000 description 25
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 25
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 25
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 24
- 229920006395 saturated elastomer Polymers 0.000 description 24
- 238000003756 stirring Methods 0.000 description 24
- 229910052757 nitrogen Chemical group 0.000 description 23
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 22
- 239000004480 active ingredient Substances 0.000 description 22
- 238000001816 cooling Methods 0.000 description 22
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 22
- 102100034159 Beta-3 adrenergic receptor Human genes 0.000 description 21
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 21
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 21
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 21
- 239000002904 solvent Substances 0.000 description 21
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 20
- 125000006268 biphenyl-3-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C([H])C(*)=C([H])C([H])=C1[H] 0.000 description 20
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 20
- 238000001914 filtration Methods 0.000 description 20
- 239000000843 powder Substances 0.000 description 20
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 19
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 description 19
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 19
- 239000007788 liquid Substances 0.000 description 19
- 239000000825 pharmaceutical preparation Substances 0.000 description 19
- 229940127557 pharmaceutical product Drugs 0.000 description 19
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 18
- 125000003118 aryl group Chemical group 0.000 description 18
- 239000000284 extract Substances 0.000 description 18
- 229910052731 fluorine Inorganic materials 0.000 description 18
- 208000024891 symptom Diseases 0.000 description 18
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 18
- 230000034994 death Effects 0.000 description 17
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 17
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 17
- 238000001035 drying Methods 0.000 description 16
- 125000000623 heterocyclic group Chemical group 0.000 description 16
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 16
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 15
- 201000010099 disease Diseases 0.000 description 15
- 125000001072 heteroaryl group Chemical group 0.000 description 15
- 239000003921 oil Substances 0.000 description 15
- 238000007792 addition Methods 0.000 description 14
- 125000004093 cyano group Chemical group *C#N 0.000 description 14
- 125000000753 cycloalkyl group Chemical group 0.000 description 14
- 238000009472 formulation Methods 0.000 description 14
- 229910052739 hydrogen Inorganic materials 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 14
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 14
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 14
- 239000003826 tablet Substances 0.000 description 14
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 13
- 125000004429 atom Chemical group 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 13
- 239000002552 dosage form Substances 0.000 description 13
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 13
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- 239000012298 atmosphere Substances 0.000 description 12
- 239000002775 capsule Substances 0.000 description 12
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 12
- 229910052760 oxygen Inorganic materials 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 12
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 11
- 125000004776 1-fluoroethyl group Chemical group [H]C([H])([H])C([H])(F)* 0.000 description 11
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 11
- 239000011737 fluorine Substances 0.000 description 11
- 239000012071 phase Substances 0.000 description 11
- VLCMRTMCMQJSKM-UHFFFAOYSA-N phenyl-[4-phenyl-8-(trifluoromethyl)quinolin-3-yl]methanone Chemical compound C=1C=CC=CC=1C(=O)C1=CN=C2C(C(F)(F)F)=CC=CC2=C1C1=CC=CC=C1 VLCMRTMCMQJSKM-UHFFFAOYSA-N 0.000 description 11
- 229910000027 potassium carbonate Inorganic materials 0.000 description 11
- 238000006467 substitution reaction Methods 0.000 description 11
- 125000006798 (C1-C6) haloalkylamino group Chemical group 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 10
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 10
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 10
- 208000001953 Hypotension Diseases 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 235000010290 biphenyl Nutrition 0.000 description 10
- 239000004305 biphenyl Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 125000001153 fluoro group Chemical group F* 0.000 description 10
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 10
- 239000012074 organic phase Substances 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 9
- AIHIHVZYAAMDPM-QMMMGPOBSA-N [(2s)-oxiran-2-yl]methyl 3-nitrobenzenesulfonate Chemical compound [O-][N+](=O)C1=CC=CC(S(=O)(=O)OC[C@H]2OC2)=C1 AIHIHVZYAAMDPM-QMMMGPOBSA-N 0.000 description 9
- 125000000217 alkyl group Chemical group 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 9
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 9
- 239000001301 oxygen Substances 0.000 description 9
- 229910052763 palladium Inorganic materials 0.000 description 9
- 239000002244 precipitate Substances 0.000 description 9
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 9
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 9
- 229910000104 sodium hydride Inorganic materials 0.000 description 9
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 8
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 8
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 8
- 238000005481 NMR spectroscopy Methods 0.000 description 8
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 8
- 125000004533 benzofuran-5-yl group Chemical group O1C=CC2=C1C=CC(=C2)* 0.000 description 8
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 8
- 229910052794 bromium Inorganic materials 0.000 description 8
- 150000003857 carboxamides Chemical class 0.000 description 8
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 8
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 8
- 239000006260 foam Substances 0.000 description 8
- 125000000336 imidazol-5-yl group Chemical group [H]N1C([H])=NC([H])=C1[*] 0.000 description 8
- 125000002883 imidazolyl group Chemical group 0.000 description 8
- 125000000842 isoxazolyl group Chemical group 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 8
- 125000001624 naphthyl group Chemical group 0.000 description 8
- 230000037081 physical activity Effects 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 125000006413 ring segment Chemical group 0.000 description 8
- 238000010189 synthetic method Methods 0.000 description 8
- 125000000335 thiazolyl group Chemical group 0.000 description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 7
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 7
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 7
- 239000013078 crystal Substances 0.000 description 7
- 229910052805 deuterium Inorganic materials 0.000 description 7
- 239000012065 filter cake Substances 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- 125000005956 isoquinolyl group Chemical group 0.000 description 7
- 239000007937 lozenge Substances 0.000 description 7
- 125000004894 pentylamino group Chemical group C(CCCC)N* 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- ACUKKOFVWISMOI-UHFFFAOYSA-N tert-butyl n-(1-oxa-8-azaspiro[4.5]decan-3-yl)carbamate Chemical compound C1C(NC(=O)OC(C)(C)C)COC21CCNCC2 ACUKKOFVWISMOI-UHFFFAOYSA-N 0.000 description 7
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 7
- 229920002554 vinyl polymer Polymers 0.000 description 7
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 6
- 125000003636 chemical group Chemical group 0.000 description 6
- 235000019253 formic acid Nutrition 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 208000021822 hypotensive Diseases 0.000 description 6
- 230000001077 hypotensive effect Effects 0.000 description 6
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 6
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Substances CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 6
- 230000000155 isotopic effect Effects 0.000 description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 6
- 238000002953 preparative HPLC Methods 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 125000000714 pyrimidinyl group Chemical group 0.000 description 6
- 125000004548 quinolin-3-yl group Chemical group N1=CC(=CC2=CC=CC=C12)* 0.000 description 6
- 125000004550 quinolin-6-yl group Chemical group N1=CC=CC2=CC(=CC=C12)* 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 229910052717 sulfur Inorganic materials 0.000 description 6
- 239000000375 suspending agent Substances 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 229910052722 tritium Inorganic materials 0.000 description 6
- 125000006002 1,1-difluoroethyl group Chemical group 0.000 description 5
- 125000000981 3-amino-3-oxopropyl group Chemical group [H]C([*])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 5
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 5
- DOFIAZGYBIBEGI-UHFFFAOYSA-N 3-sulfanylphenol Chemical compound OC1=CC=CC(S)=C1 DOFIAZGYBIBEGI-UHFFFAOYSA-N 0.000 description 5
- 108060003345 Adrenergic Receptor Proteins 0.000 description 5
- 102000017910 Adrenergic receptor Human genes 0.000 description 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 5
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 5
- 206010013975 Dyspnoeas Diseases 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 description 5
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 5
- HQABUPZFAYXKJW-UHFFFAOYSA-N N-butylamine Natural products CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 5
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 5
- 239000002270 dispersing agent Substances 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 150000002148 esters Chemical group 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- 125000001188 haloalkyl group Chemical group 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 239000012280 lithium aluminium hydride Substances 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 5
- 230000002285 radioactive effect Effects 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- PKCLSEZPKDHERV-UHFFFAOYSA-N 1-methyl-2,3-dihydropyrido[2,3-b][1,4]oxazine Chemical compound C1=CC=C2N(C)CCOC2=N1 PKCLSEZPKDHERV-UHFFFAOYSA-N 0.000 description 4
- 125000000979 2-amino-2-oxoethyl group Chemical group [H]C([*])([H])C(=O)N([H])[H] 0.000 description 4
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 4
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 4
- KDSNLYIMUZNERS-UHFFFAOYSA-N 2-methylpropanamine Chemical compound CC(C)CN KDSNLYIMUZNERS-UHFFFAOYSA-N 0.000 description 4
- INGLHGWHMKLCMO-UHFFFAOYSA-N 3-cyclopropylsulfonylphenol Chemical compound C1(CC1)S(=O)(=O)C=1C=C(C=CC=1)O INGLHGWHMKLCMO-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- 125000004608 5,6,7,8-tetrahydroquinolinyl group Chemical group N1=C(C=CC=2CCCCC12)* 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 4
- MRMSCGBPOGFFHW-UHFFFAOYSA-N CCCCCCCC(CC)NCC(C)O Chemical compound CCCCCCCC(CC)NCC(C)O MRMSCGBPOGFFHW-UHFFFAOYSA-N 0.000 description 4
- DOJFMLOOOJIPHT-UHFFFAOYSA-N CN1C2=C(OCC1)N=CC(=C2)S(=O)(=O)Cl Chemical compound CN1C2=C(OCC1)N=CC(=C2)S(=O)(=O)Cl DOJFMLOOOJIPHT-UHFFFAOYSA-N 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 4
- 101000652482 Homo sapiens TBC1 domain family member 8 Proteins 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- 102100030302 TBC1 domain family member 8 Human genes 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 125000004244 benzofuran-2-yl group Chemical group [H]C1=C(*)OC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 4
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 4
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 4
- KHROHHIWLMXRBO-UHFFFAOYSA-N benzyl 3-[(2-methylpropan-2-yl)oxycarbonylamino]-1-oxa-8-azaspiro[4.5]decane-8-carboxylate Chemical compound C(C)(C)(C)OC(=O)NC1COC2(C1)CCN(CC2)C(=O)OCC1=CC=CC=C1 KHROHHIWLMXRBO-UHFFFAOYSA-N 0.000 description 4
- HMOLUMBNXPQUPP-UHFFFAOYSA-N benzyl 3-amino-1-oxa-8-azaspiro[4.5]decane-8-carboxylate Chemical compound NC1COC2(C1)CCN(CC2)C(=O)OCC1=CC=CC=C1 HMOLUMBNXPQUPP-UHFFFAOYSA-N 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 125000006309 butyl amino group Chemical group 0.000 description 4
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 4
- 238000004296 chiral HPLC Methods 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 239000012230 colorless oil Substances 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000001631 hypertensive effect Effects 0.000 description 4
- 230000036543 hypotension Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 4
- 239000000376 reactant Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 238000004808 supercritical fluid chromatography Methods 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- AJZHMTCIGBAHGL-SNVBAGLBSA-N (2S)-2-[(3-cyclopropylsulfonylphenoxy)methyl]oxirane Chemical compound C1(CC1)S(=O)(=O)C=1C=C(OC[C@H]2OC2)C=CC=1 AJZHMTCIGBAHGL-SNVBAGLBSA-N 0.000 description 3
- JFZRVAHMYXVTRG-GFCCVEGCSA-N (2S)-2-[[3-(cyclopropylmethylsulfonyl)phenoxy]methyl]oxirane Chemical compound C1(CC1)CS(=O)(=O)C=1C=C(OC[C@H]2OC2)C=CC=1 JFZRVAHMYXVTRG-GFCCVEGCSA-N 0.000 description 3
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 3
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 3
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 3
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 3
- WWQQPSDIIVXFOX-UHFFFAOYSA-N 5-bromo-2-chloro-3-nitropyridine Chemical compound [O-][N+](=O)C1=CC(Br)=CN=C1Cl WWQQPSDIIVXFOX-UHFFFAOYSA-N 0.000 description 3
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000012425 OXONE® Substances 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- IPGPIDFPWVWUNU-UHFFFAOYSA-N benzyl 3-methylsulfonyloxy-1-oxa-8-azaspiro[4.5]decane-8-carboxylate Chemical compound CS(=O)(=O)OC1COC2(C1)CCN(CC2)C(=O)OCC1=CC=CC=C1 IPGPIDFPWVWUNU-UHFFFAOYSA-N 0.000 description 3
- VZOVOHRDLOYBJX-UHFFFAOYSA-N benzyl 4-oxopiperidine-1-carboxylate Chemical compound C1CC(=O)CCN1C(=O)OCC1=CC=CC=C1 VZOVOHRDLOYBJX-UHFFFAOYSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 125000005347 halocycloalkyl group Chemical group 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 125000004498 isoxazol-4-yl group Chemical group O1N=CC(=C1)* 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- 229940017219 methyl propionate Drugs 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- OPECTNGATDYLSS-UHFFFAOYSA-N naphthalene-2-sulfonyl chloride Chemical compound C1=CC=CC2=CC(S(=O)(=O)Cl)=CC=C21 OPECTNGATDYLSS-UHFFFAOYSA-N 0.000 description 3
- 239000006199 nebulizer Substances 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- UENWRTRMUIOCKN-UHFFFAOYSA-N phenylmethylmercaptan Natural products SCC1=CC=CC=C1 UENWRTRMUIOCKN-UHFFFAOYSA-N 0.000 description 3
- OKBMCNHOEMXPTM-UHFFFAOYSA-M potassium peroxymonosulfate Chemical compound [K+].OOS([O-])(=O)=O OKBMCNHOEMXPTM-UHFFFAOYSA-M 0.000 description 3
- AUDKCUOUBLCZQR-UHFFFAOYSA-N quinoline-6-sulfonyl chloride Chemical compound N1=CC=CC2=CC(S(=O)(=O)Cl)=CC=C21 AUDKCUOUBLCZQR-UHFFFAOYSA-N 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 2
- BRLQWZUYTZBJKN-GSVOUGTGSA-N (+)-Epichlorohydrin Chemical compound ClC[C@@H]1CO1 BRLQWZUYTZBJKN-GSVOUGTGSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 2
- LTNOCYVHAPCRKF-SECBINFHSA-N (2S)-2-[[3-(fluoromethylsulfonyl)phenoxy]methyl]oxirane Chemical compound FCS(=O)(=O)C1=CC=CC(OC[C@@H]2CO2)=C1 LTNOCYVHAPCRKF-SECBINFHSA-N 0.000 description 2
- GJNBVOLCBVPXKC-LLVKDONJSA-N (2S)-2-[[3-(methylsulfonylmethyl)phenoxy]methyl]oxirane Chemical compound CS(=O)(=O)CC=1C=C(OC[C@H]2OC2)C=CC=1 GJNBVOLCBVPXKC-LLVKDONJSA-N 0.000 description 2
- PAORVUMOXXAMPL-SECBINFHSA-N (2s)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoyl chloride Chemical compound CO[C@](C(Cl)=O)(C(F)(F)F)C1=CC=CC=C1 PAORVUMOXXAMPL-SECBINFHSA-N 0.000 description 2
- WTWOGSOQBNDDLE-LBPRGKRZSA-N (3S)-7-benzylsulfanyl-1,3-dimethyl-2,3-dihydropyrido[2,3-b][1,4]oxazine Chemical compound C(C1=CC=CC=C1)SC1=CC2=C(O[C@H](CN2C)C)N=C1 WTWOGSOQBNDDLE-LBPRGKRZSA-N 0.000 description 2
- AHOUBRCZNHFOSL-SVLNYFRSSA-N (3s,4r)-3-[(2,2-dideuterio-1,3-benzodioxol-5-yl)oxymethyl]-4-(4-fluorophenyl)piperidine Chemical compound C1([C@@H]2CCNC[C@H]2COC2=CC=C3OC(OC3=C2)([2H])[2H])=CC=C(F)C=C1 AHOUBRCZNHFOSL-SVLNYFRSSA-N 0.000 description 2
- YHKNTKJZPGUEQK-GGYWPGCISA-N (8-naphthalen-2-ylsulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl) N-[[(2S)-oxiran-2-yl]methyl]carbamate Chemical compound C1=C(C=CC2=CC=CC=C12)S(=O)(=O)N1CCC2(CC(CO2)OC(NC[C@@H]2OC2)=O)CC1 YHKNTKJZPGUEQK-GGYWPGCISA-N 0.000 description 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- MEOWZRWUCMVENE-UHFFFAOYSA-N 1-(2-methoxyethyl)-2,3-dihydropyrido[2,3-b][1,4]oxazine-7-sulfonyl chloride Chemical compound COCCN1C2=C(OCC1)N=CC(=C2)S(=O)(=O)Cl MEOWZRWUCMVENE-UHFFFAOYSA-N 0.000 description 2
- XPVVGLJVCREBPU-UHFFFAOYSA-N 1-(cyclopropylmethylsulfonyl)-3-methoxybenzene Chemical compound COC1=CC=CC(=C1)S(=O)(=O)CC1CC1 XPVVGLJVCREBPU-UHFFFAOYSA-N 0.000 description 2
- YMYKXUBZPNRRQD-UHFFFAOYSA-N 1-methoxy-3-methylsulfonylbenzene Chemical compound COC1=CC=CC(S(C)(=O)=O)=C1 YMYKXUBZPNRRQD-UHFFFAOYSA-N 0.000 description 2
- QGONQZDATSXDKK-UHFFFAOYSA-N 1h-indole-3-sulfonyl chloride Chemical compound C1=CC=C2C(S(=O)(=O)Cl)=CNC2=C1 QGONQZDATSXDKK-UHFFFAOYSA-N 0.000 description 2
- CKSMAKADIVZCFK-UHFFFAOYSA-N 2,2-difluoro-2-(3-methoxyphenyl)sulfonylethanol Chemical compound FC(CO)(S(=O)(=O)C1=CC(=CC=C1)OC)F CKSMAKADIVZCFK-UHFFFAOYSA-N 0.000 description 2
- LYJDOWLQIXXCCQ-UHFFFAOYSA-N 2-methyl-1h-pyridine-2,3-diamine Chemical compound CC1(N)NC=CC=C1N LYJDOWLQIXXCCQ-UHFFFAOYSA-N 0.000 description 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 2
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 2
- XFBOWJXENHBSBQ-UHFFFAOYSA-N 3-(1,1-difluoro-2-hydroxyethyl)sulfonylphenol Chemical compound OCC(F)(F)S(=O)(=O)C1=CC=CC(O)=C1 XFBOWJXENHBSBQ-UHFFFAOYSA-N 0.000 description 2
- BQDUNOMMYOKHEP-GQALSZNTSA-N 3-(2,5-difluorophenyl)-7-[1,1,1,3,3,3-hexadeuterio-2-(trideuteriomethyl)propan-2-yl]-6-[(2-methyl-1,2,4-triazol-3-yl)methoxy]-[1,2,4]triazolo[4,3-b]pyridazine Chemical compound N12N=C(OCC=3N(N=CN=3)C)C(C(C([2H])([2H])[2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])=CC2=NN=C1C1=CC(F)=CC=C1F BQDUNOMMYOKHEP-GQALSZNTSA-N 0.000 description 2
- SAFKIUKLLDCKLW-UHFFFAOYSA-N 3-(2-hydroxyethylsulfanyl)phenol Chemical compound OCCSC1=CC=CC(O)=C1 SAFKIUKLLDCKLW-UHFFFAOYSA-N 0.000 description 2
- LZCPFLJHLGRZAM-UHFFFAOYSA-N 3-(2-hydroxyethylsulfonyl)phenol Chemical compound OCCS(=O)(=O)C1=CC=CC(O)=C1 LZCPFLJHLGRZAM-UHFFFAOYSA-N 0.000 description 2
- DCBIPHPTIKRPET-UHFFFAOYSA-N 3-(3-chloropropylsulfanyl)phenol Chemical compound OC1=CC=CC(SCCCCl)=C1 DCBIPHPTIKRPET-UHFFFAOYSA-N 0.000 description 2
- NUJGLCYDLMZLLA-UHFFFAOYSA-N 3-(3-chloropropylsulfonyl)phenol Chemical compound OC1=CC=CC(S(=O)(=O)CCCCl)=C1 NUJGLCYDLMZLLA-UHFFFAOYSA-N 0.000 description 2
- WAODSUJAVVYUTH-UHFFFAOYSA-N 3-(cyclopropylmethylsulfonyl)phenol Chemical compound C1(CC1)CS(=O)(=O)C=1C=C(C=CC=1)O WAODSUJAVVYUTH-UHFFFAOYSA-N 0.000 description 2
- PUTQJICEDYSGKD-UHFFFAOYSA-N 3-[1-(hydroxymethyl)cyclobutyl]sulfonylphenol Chemical compound OCC1(CCC1)S(=O)(=O)C=1C=C(C=CC=1)O PUTQJICEDYSGKD-UHFFFAOYSA-N 0.000 description 2
- BICWTEAVAUEQDY-UHFFFAOYSA-N 3-[1-(hydroxymethyl)cyclopropyl]sulfonylphenol Chemical compound OCC1(CC1)S(=O)(=O)C=1C=C(C=CC=1)O BICWTEAVAUEQDY-UHFFFAOYSA-N 0.000 description 2
- WSCHKAFCICHQRT-UHFFFAOYSA-N 3-cyclopropylsulfanylphenol Chemical compound C1(CC1)SC=1C=C(C=CC=1)O WSCHKAFCICHQRT-UHFFFAOYSA-N 0.000 description 2
- QXHSADJKACGOQH-UHFFFAOYSA-N 3-ethylsulfonylphenol Chemical compound CCS(=O)(=O)C1=CC=CC(O)=C1 QXHSADJKACGOQH-UHFFFAOYSA-N 0.000 description 2
- QMVAZEHZOPDGHA-UHFFFAOYSA-N 3-methoxybenzenethiol Chemical compound COC1=CC=CC(S)=C1 QMVAZEHZOPDGHA-UHFFFAOYSA-N 0.000 description 2
- PSAYFBGYTSGNQR-UHFFFAOYSA-N 3-methylimidazo[4,5-b]pyridine-6-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CN=C2N(C)C=NC2=C1 PSAYFBGYTSGNQR-UHFFFAOYSA-N 0.000 description 2
- MRZXZRGNTXHLKA-UHFFFAOYSA-N 3-methylsulfonylphenol Chemical compound CS(=O)(=O)C1=CC=CC(O)=C1 MRZXZRGNTXHLKA-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- IWKKJBMZOOIHJD-UHFFFAOYSA-N 6-benzylsulfanyl-3-methylimidazo[4,5-b]pyridine Chemical compound C(C1=CC=CC=C1)SC=1C=C2C(=NC=1)N(C=N2)C IWKKJBMZOOIHJD-UHFFFAOYSA-N 0.000 description 2
- QZZPOLTYNRWJRZ-UHFFFAOYSA-N 7-benzylsulfanyl-1,3,3-trimethyl-2H-pyrido[2,3-b][1,4]oxazine Chemical compound C(C1=CC=CC=C1)SC1=CC2=C(OC(CN2C)(C)C)N=C1 QZZPOLTYNRWJRZ-UHFFFAOYSA-N 0.000 description 2
- OZHOMNMWSATHAZ-UHFFFAOYSA-N 7-benzylsulfanyl-1,8-dimethyl-2,3-dihydropyrido[2,3-b][1,4]oxazine Chemical compound C(C1=CC=CC=C1)SC1=C(C2=C(OCCN2C)N=C1)C OZHOMNMWSATHAZ-UHFFFAOYSA-N 0.000 description 2
- GQTRTKSUEIXZGW-UHFFFAOYSA-N 7-bromospiro[1,2-dihydropyrido[2,3-b][1,4]oxazine-3,1'-cyclopropane] Chemical compound BrC1=CC2=C(OC3(CC3)CN2)N=C1 GQTRTKSUEIXZGW-UHFFFAOYSA-N 0.000 description 2
- XASOHFCUIQARJT-UHFFFAOYSA-N 8-methoxy-6-[7-(2-morpholin-4-ylethoxy)imidazo[1,2-a]pyridin-3-yl]-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinolin-1-one Chemical compound C(N1C(=O)C2=C(OC)C=C(C=3N4C(=NC=3)C=C(C=C4)OCCN3CCOCC3)C=C2CC1)C(F)(F)F XASOHFCUIQARJT-UHFFFAOYSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 208000030090 Acute Disease Diseases 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- VIXYQYHHMUUUKO-UHFFFAOYSA-N C(C1=CC=CC=C1)SC1=CC2=C(OCCN2C)N=C1 Chemical compound C(C1=CC=CC=C1)SC1=CC2=C(OCCN2C)N=C1 VIXYQYHHMUUUKO-UHFFFAOYSA-N 0.000 description 2
- MZKBTFPJIPZEPL-UHFFFAOYSA-N CCCCOC(NC(C1)COC1(CC1)CCN1S(C1=CC2=CC=CC=C2C=C1)(=O)=O)=O Chemical group CCCCOC(NC(C1)COC1(CC1)CCN1S(C1=CC2=CC=CC=C2C=C1)(=O)=O)=O MZKBTFPJIPZEPL-UHFFFAOYSA-N 0.000 description 2
- HISQFHADGJXGKB-UHFFFAOYSA-N CCN1C=C(C(=O)C2=C1C=CC=C2)S(Cl)(=O)=O Chemical compound CCN1C=C(C(=O)C2=C1C=CC=C2)S(Cl)(=O)=O HISQFHADGJXGKB-UHFFFAOYSA-N 0.000 description 2
- CSEQLZNHLWFBKX-UHFFFAOYSA-N COCCNC(C(=O)NNCC(F)(F)F)(NCCCN)NCCN Chemical compound COCCNC(C(=O)NNCC(F)(F)F)(NCCCN)NCCN CSEQLZNHLWFBKX-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- AYHPSSYMLCQJJG-UHFFFAOYSA-N N1C=CCC2=CC=CC=C12.[O] Chemical compound N1C=CCC2=CC=CC=C12.[O] AYHPSSYMLCQJJG-UHFFFAOYSA-N 0.000 description 2
- RVZSTJKIQFKBAG-UHFFFAOYSA-N OC(CC1(CCN(CC1)C(=O)OCC1=CC=CC=C1)O)CO Chemical compound OC(CC1(CCN(CC1)C(=O)OCC1=CC=CC=C1)O)CO RVZSTJKIQFKBAG-UHFFFAOYSA-N 0.000 description 2
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- ZSBLYZDXEXADSH-UHFFFAOYSA-N [1-(3-methoxyphenyl)sulfonylcyclobutyl]methanol Chemical compound COC=1C=C(C=CC=1)S(=O)(=O)C1(CCC1)CO ZSBLYZDXEXADSH-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 150000001299 aldehydes Chemical group 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 2
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 230000005587 bubbling Effects 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 2
- 230000001451 cardiotoxic effect Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- 239000012954 diazonium Substances 0.000 description 2
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 2
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 238000013213 extrapolation Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002596 lactones Chemical group 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- HANFVYLNKLUVMM-UHFFFAOYSA-N methyl quinoline-6-sulfonate Chemical compound N1=CC=CC2=CC(=CC=C12)S(=O)(=O)OC HANFVYLNKLUVMM-UHFFFAOYSA-N 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000006574 non-aromatic ring group Chemical group 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 239000006201 parenteral dosage form Substances 0.000 description 2
- 229960002296 paroxetine Drugs 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 238000012746 preparative thin layer chromatography Methods 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- VSAXLHSQUHPTCS-UHFFFAOYSA-N quinoline-3-sulfonyl chloride Chemical compound C1=CC=CC2=CC(S(=O)(=O)Cl)=CN=C21 VSAXLHSQUHPTCS-UHFFFAOYSA-N 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- VKCIOBTZODPZOA-UHFFFAOYSA-N tert-butyl N-(8-naphthalen-2-ylsulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl)carbamate Chemical compound C1=C(C=CC2=CC=CC=C12)S(=O)(=O)N1CCC2(CC(CO2)NC(OC(C)(C)C)=O)CC1 VKCIOBTZODPZOA-UHFFFAOYSA-N 0.000 description 2
- ACUKKOFVWISMOI-JTQLQIEISA-N tert-butyl N-[(3S)-1-oxa-8-azaspiro[4.5]decan-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@H]1COC2(C1)CCNCC2 ACUKKOFVWISMOI-JTQLQIEISA-N 0.000 description 2
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical group CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000004306 triazinyl group Chemical group 0.000 description 2
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
- BWHDROKFUHTORW-UHFFFAOYSA-N tritert-butylphosphane Chemical compound CC(C)(C)P(C(C)(C)C)C(C)(C)C BWHDROKFUHTORW-UHFFFAOYSA-N 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- NUQSPJWEWTVPQR-AMVUTOCUSA-N (2S)-1-(3-cyclobutylsulfonylphenoxy)-3-[(8-naphthalen-2-ylsulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl)amino]propan-2-ol Chemical compound C1(CCC1)S(=O)(=O)C=1C=C(OC[C@H](CNC2COC3(C2)CCN(CC3)S(=O)(=O)C2=CC3=CC=CC=C3C=C2)O)C=CC=1 NUQSPJWEWTVPQR-AMVUTOCUSA-N 0.000 description 1
- IEAKDXQMJZPLDG-GEVKEYJPSA-N (2S)-1-(3-cyclopentylsulfonylphenoxy)-3-[(8-naphthalen-2-ylsulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl)amino]propan-2-ol Chemical compound C1(CCCC1)S(=O)(=O)C=1C=C(OC[C@H](CNC2COC3(C2)CCN(CC3)S(=O)(=O)C2=CC3=CC=CC=C3C=C2)O)C=CC=1 IEAKDXQMJZPLDG-GEVKEYJPSA-N 0.000 description 1
- IFPRXDTVRADNRS-BBMPLOMVSA-N (2S)-1-(3-ethylsulfonylphenoxy)-3-[(8-naphthalen-2-ylsulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl)amino]propan-2-ol Chemical compound C(C)S(=O)(=O)C=1C=C(OC[C@H](CNC2COC3(C2)CCN(CC3)S(=O)(=O)C2=CC3=CC=CC=C3C=C2)O)C=CC=1 IFPRXDTVRADNRS-BBMPLOMVSA-N 0.000 description 1
- IFPRXDTVRADNRS-DQEYMECFSA-N (2S)-1-(3-ethylsulfonylphenoxy)-3-[[(3S)-8-naphthalen-2-ylsulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]propan-2-ol Chemical compound CCS(=O)(=O)C1=CC=CC(OC[C@@H](O)CN[C@@H]2COC3(C2)CCN(CC3)S(=O)(=O)C2=CC3=CC=CC=C3C=C2)=C1 IFPRXDTVRADNRS-DQEYMECFSA-N 0.000 description 1
- FNRSEWMHJZJOIW-KEKNWZKVSA-N (2S)-1-(3-methylsulfonylphenoxy)-3-[(8-quinolin-6-ylsulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl)amino]propan-2-ol Chemical compound CS(=O)(=O)C=1C=C(OC[C@H](CNC2COC3(C2)CCN(CC3)S(=O)(=O)C=2C=C3C=CC=NC3=CC=2)O)C=CC=1 FNRSEWMHJZJOIW-KEKNWZKVSA-N 0.000 description 1
- ULOHKVQKBIEAIY-ZEQRLZLVSA-N (2S)-1-(3-methylsulfonylphenoxy)-3-[[(3S)-8-naphthalen-2-ylsulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]propan-2-ol Chemical compound CS(=O)(=O)C=1C=C(OC[C@H](CN[C@@H]2COC3(C2)CCN(CC3)S(=O)(=O)C2=CC3=CC=CC=C3C=C2)O)C=CC=1 ULOHKVQKBIEAIY-ZEQRLZLVSA-N 0.000 description 1
- HPNIDYKGGYZBLE-VXKWHMMOSA-N (2S)-1-(3-methylsulfonylphenoxy)-3-[[(3S)-8-quinolin-3-ylsulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]propan-2-ol Chemical compound CS(=O)(=O)C1=CC=CC(OC[C@@H](O)CN[C@@H]2COC3(C2)CCN(CC3)S(=O)(=O)C2=CC3=CC=CC=C3N=C2)=C1 HPNIDYKGGYZBLE-VXKWHMMOSA-N 0.000 description 1
- BDBFFNAWBRWIFU-CGAIIQECSA-N (2S)-1-(3-methylsulfonylphenoxy)-3-[[8-(3-pyridin-2-ylphenyl)sulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]propan-2-ol Chemical compound CS(=O)(=O)C=1C=C(OC[C@H](CNC2COC3(C2)CCN(CC3)S(=O)(=O)C2=CC(=CC=C2)C2=NC=CC=C2)O)C=CC=1 BDBFFNAWBRWIFU-CGAIIQECSA-N 0.000 description 1
- JWGSHLSTFFYQRJ-BBMPLOMVSA-N (2S)-1-(3-methylsulfonylphenoxy)-3-[[8-(3-pyridin-3-ylphenyl)sulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]propan-2-ol Chemical compound CS(=O)(=O)C=1C=C(OC[C@H](CNC2COC3(C2)CCN(CC3)S(=O)(=O)C2=CC(=CC=C2)C=2C=NC=CC=2)O)C=CC=1 JWGSHLSTFFYQRJ-BBMPLOMVSA-N 0.000 description 1
- WSUHQTIPGABJQX-BBMPLOMVSA-N (2S)-1-(3-methylsulfonylphenoxy)-3-[[8-(3-pyridin-4-ylphenyl)sulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]propan-2-ol Chemical compound CS(=O)(=O)C=1C=C(OC[C@H](CNC2COC3(C2)CCN(CC3)S(=O)(=O)C2=CC(=CC=C2)C2=CC=NC=C2)O)C=CC=1 WSUHQTIPGABJQX-BBMPLOMVSA-N 0.000 description 1
- UAUYIPPVEBMISP-CGAIIQECSA-N (2S)-1-(3-methylsulfonylphenoxy)-3-[[8-(3-pyrimidin-5-ylphenyl)sulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]propan-2-ol Chemical compound CS(=O)(=O)C=1C=C(OC[C@H](CNC2COC3(C2)CCN(CC3)S(=O)(=O)C2=CC(=CC=C2)C=2C=NC=NC=2)O)C=CC=1 UAUYIPPVEBMISP-CGAIIQECSA-N 0.000 description 1
- UFMGFPCQXGGQAJ-CGAIIQECSA-N (2S)-1-(3-methylsulfonylphenoxy)-3-[[8-(5,6,7,8-tetrahydronaphthalen-2-ylsulfonyl)-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]propan-2-ol Chemical compound CS(=O)(=O)C=1C=C(OC[C@H](CNC2COC3(C2)CCN(CC3)S(=O)(=O)C2=CC=3CCCCC=3C=C2)O)C=CC=1 UFMGFPCQXGGQAJ-CGAIIQECSA-N 0.000 description 1
- FTVPQUIQVZIVAE-WCSIJFPASA-N (2S)-1-(3-methylsulfonylphenoxy)-3-[[8-(5-phenylthiophen-2-yl)sulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]propan-2-ol Chemical compound CS(=O)(=O)C=1C=C(OC[C@H](CNC2COC3(C2)CCN(CC3)S(=O)(=O)C=2SC(=CC=2)C2=CC=CC=C2)O)C=CC=1 FTVPQUIQVZIVAE-WCSIJFPASA-N 0.000 description 1
- WTQDFRAENJUUIX-AMVUTOCUSA-N (2S)-1-(3-methylsulfonylphenoxy)-3-[[8-[3-(1-propylpyrazol-4-yl)phenyl]sulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]propan-2-ol Chemical compound CS(=O)(=O)C=1C=C(OC[C@H](CNC2COC3(C2)CCN(CC3)S(=O)(=O)C2=CC(=CC=C2)C=2C=NN(C=2)CCC)O)C=CC=1 WTQDFRAENJUUIX-AMVUTOCUSA-N 0.000 description 1
- XBBKNTWPUDGVFC-ANYOKISRSA-N (2S)-1-(3-methylsulfonylphenoxy)-3-[[8-[3-(trifluoromethyl)phenyl]sulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]propan-2-ol Chemical compound CS(=O)(=O)C=1C=C(OC[C@H](CNC2COC3(C2)CCN(CC3)S(=O)(=O)C2=CC(=CC=C2)C(F)(F)F)O)C=CC=1 XBBKNTWPUDGVFC-ANYOKISRSA-N 0.000 description 1
- DLSITFBGHYZQRN-CPRJBALCSA-N (2S)-1-(3-methylsulfonylphenoxy)-3-[[8-[3-[4-[(2,2,2-trifluoroethylamino)methyl]phenyl]phenyl]sulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]propan-2-ol Chemical compound CS(=O)(=O)C=1C=C(OC[C@H](CNC2COC3(C2)CCN(CC3)S(=O)(=O)C=2C=C(C=CC=2)C2=CC=C(C=C2)CNCC(F)(F)F)O)C=CC=1 DLSITFBGHYZQRN-CPRJBALCSA-N 0.000 description 1
- FQJSHQJAYFRYJI-CGAIIQECSA-N (2S)-1-(4-methylsulfonylphenoxy)-3-[(8-naphthalen-2-ylsulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl)amino]propan-2-ol Chemical compound CS(=O)(=O)C1=CC=C(OC[C@H](CNC2COC3(C2)CCN(CC3)S(=O)(=O)C2=CC3=CC=CC=C3C=C2)O)C=C1 FQJSHQJAYFRYJI-CGAIIQECSA-N 0.000 description 1
- SCGYFABEUDTFBG-AMVUTOCUSA-N (2S)-1-[(8-naphthalen-2-ylsulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl)amino]-3-(3-propan-2-ylsulfonylphenoxy)propan-2-ol Chemical compound C(C)(C)S(=O)(=O)C=1C=C(OC[C@H](CNC2COC3(C2)CCN(CC3)S(=O)(=O)C2=CC3=CC=CC=C3C=C2)O)C=CC=1 SCGYFABEUDTFBG-AMVUTOCUSA-N 0.000 description 1
- WZOCCOWSTIXEAI-BBMPLOMVSA-N (2S)-1-[(8-naphthalen-2-ylsulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl)amino]-3-[3-(3,3,3-trifluoropropylsulfonyl)phenoxy]propan-2-ol Chemical compound C1=C(C=CC2=CC=CC=C12)S(=O)(=O)N1CCC2(CC(CO2)NC[C@@H](COC2=CC(=CC=C2)S(=O)(=O)CCC(F)(F)F)O)CC1 WZOCCOWSTIXEAI-BBMPLOMVSA-N 0.000 description 1
- NJFBSBWKPOGIII-AMVUTOCUSA-N (2S)-1-[(8-naphthalen-2-ylsulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl)amino]-3-[3-(4,4,4-trifluorobutylsulfonyl)phenoxy]propan-2-ol Chemical compound C1=C(C=CC2=CC=CC=C12)S(=O)(=O)N1CCC2(CC(CO2)NC[C@@H](COC2=CC(=CC=C2)S(=O)(=O)CCCC(F)(F)F)O)CC1 NJFBSBWKPOGIII-AMVUTOCUSA-N 0.000 description 1
- XIRNBCRDAOZLNR-BBMPLOMVSA-N (2S)-1-[3-(2-aminoethylsulfonyl)phenoxy]-3-[(8-naphthalen-2-ylsulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl)amino]propan-2-ol Chemical compound NCCS(=O)(=O)C=1C=C(OC[C@H](CNC2COC3(C2)CCN(CC3)S(=O)(=O)C2=CC3=CC=CC=C3C=C2)O)C=CC=1 XIRNBCRDAOZLNR-BBMPLOMVSA-N 0.000 description 1
- VBJKDHPUWGDJCV-BBMPLOMVSA-N (2S)-1-[3-(2-hydroxyethylsulfonyl)phenoxy]-3-[(8-naphthalen-2-ylsulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl)amino]propan-2-ol Chemical compound OCCS(=O)(=O)c1cccc(OC[C@@H](O)CNC2COC3(C2)CCN(CC3)S(=O)(=O)c2ccc3ccccc3c2)c1 VBJKDHPUWGDJCV-BBMPLOMVSA-N 0.000 description 1
- SMQLQBNQFBWWMM-UIOOFZCWSA-N (2S)-1-[3-(2-hydroxyethylsulfonyl)phenoxy]-3-[[(3S)-8-[3-(6-methylpyridin-2-yl)phenyl]sulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]propan-2-ol Chemical compound CC1=CC=CC(=N1)C1=CC=CC(=C1)S(=O)(=O)N1CCC2(C[C@@H](CO2)NC[C@H](O)COC2=CC(=CC=C2)S(=O)(=O)CCO)CC1 SMQLQBNQFBWWMM-UIOOFZCWSA-N 0.000 description 1
- VBJKDHPUWGDJCV-DQEYMECFSA-N (2S)-1-[3-(2-hydroxyethylsulfonyl)phenoxy]-3-[[(3S)-8-naphthalen-2-ylsulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]propan-2-ol Chemical compound OCCS(=O)(=O)C=1C=C(OC[C@H](CN[C@@H]2COC3(C2)CCN(CC3)S(=O)(=O)C2=CC3=CC=CC=C3C=C2)O)C=CC=1 VBJKDHPUWGDJCV-DQEYMECFSA-N 0.000 description 1
- QVSSSBLOBJMMGN-GEVKEYJPSA-N (2S)-1-[3-(2-methylpropylsulfonyl)phenoxy]-3-[(8-naphthalen-2-ylsulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl)amino]propan-2-ol Chemical compound C(C(C)C)S(=O)(=O)C=1C=C(OC[C@H](CNC2COC3(C2)CCN(CC3)S(=O)(=O)C2=CC3=CC=CC=C3C=C2)O)C=CC=1 QVSSSBLOBJMMGN-GEVKEYJPSA-N 0.000 description 1
- BZYJLAYSNOTRPP-CPRJBALCSA-N (2S)-1-[3-(3-methylbutylsulfonyl)phenoxy]-3-[(8-naphthalen-2-ylsulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl)amino]propan-2-ol Chemical compound C(CC(C)C)S(=O)(=O)C=1C=C(OC[C@H](CNC2COC3(C2)CCN(CC3)S(=O)(=O)C2=CC3=CC=CC=C3C=C2)O)C=CC=1 BZYJLAYSNOTRPP-CPRJBALCSA-N 0.000 description 1
- DXQJFBDSKVPZCT-CPRJBALCSA-N (2S)-1-[3-(cyclobutylmethylsulfonyl)phenoxy]-3-[(8-naphthalen-2-ylsulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl)amino]propan-2-ol Chemical compound C1(CCC1)CS(=O)(=O)C=1C=C(OC[C@H](CNC2COC3(C2)CCN(CC3)S(=O)(=O)C2=CC3=CC=CC=C3C=C2)O)C=CC=1 DXQJFBDSKVPZCT-CPRJBALCSA-N 0.000 description 1
- DNDLJWKEVBIMNB-GEVKEYJPSA-N (2S)-1-[3-(cyclopropylmethylsulfonyl)phenoxy]-3-[(8-naphthalen-2-ylsulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl)amino]propan-2-ol Chemical compound C1(CC1)CS(=O)(=O)C=1C=C(OC[C@H](CNC2COC3(C2)CCN(CC3)S(=O)(=O)C2=CC3=CC=CC=C3C=C2)O)C=CC=1 DNDLJWKEVBIMNB-GEVKEYJPSA-N 0.000 description 1
- DEWXHHAIVSIOFX-CGAIIQECSA-N (2S)-1-[3-(fluoromethylsulfonyl)phenoxy]-3-[(8-naphthalen-2-ylsulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl)amino]propan-2-ol Chemical compound FCS(=O)(=O)C=1C=C(OC[C@H](CNC2COC3(C2)CCN(CC3)S(=O)(=O)C2=CC3=CC=CC=C3C=C2)O)C=CC=1 DEWXHHAIVSIOFX-CGAIIQECSA-N 0.000 description 1
- BODWAJZSUDQXOG-WNMGUVTHSA-N (2S)-1-[3-[(2,2-difluorocyclopropyl)methylsulfonyl]phenoxy]-3-[(8-naphthalen-2-ylsulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl)amino]propan-2-ol Chemical compound FC1(C(C1)CS(=O)(=O)C=1C=C(OC[C@H](CNC2COC3(C2)CCN(CC3)S(=O)(=O)C2=CC3=CC=CC=C3C=C2)O)C=CC=1)F BODWAJZSUDQXOG-WNMGUVTHSA-N 0.000 description 1
- YDYFNNSKQPUTPB-KYJUHHDHSA-N (2S)-1-[3-[1-(hydroxymethyl)cyclopropyl]sulfonylphenoxy]-3-[[(3S)-8-[3-[4-[(2,2,2-trifluoroethylamino)methyl]phenyl]phenyl]sulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]propan-2-ol Chemical compound OCC1(CC1)S(=O)(=O)C=1C=C(OC[C@H](CN[C@@H]2COC3(C2)CCN(CC3)S(=O)(=O)C=2C=C(C=CC=2)C2=CC=C(C=C2)CNCC(F)(F)F)O)C=CC=1 YDYFNNSKQPUTPB-KYJUHHDHSA-N 0.000 description 1
- ZPBCOJQTGITLTM-SFTDATJTSA-N (2S)-1-[3-[1-(hydroxymethyl)cyclopropyl]sulfonylphenoxy]-3-[[(3S)-8-pyridin-3-ylsulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]propan-2-ol Chemical compound OCC1(CC1)S(=O)(=O)C1=CC=CC(OC[C@@H](O)CN[C@@H]2COC3(C2)CCN(CC3)S(=O)(=O)C2=CC=CN=C2)=C1 ZPBCOJQTGITLTM-SFTDATJTSA-N 0.000 description 1
- SQAORIPHBFMSKS-VXKWHMMOSA-N (2S)-1-[[(3S)-8-(3-bromo-2-methylphenyl)sulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]-3-[3-[1-(hydroxymethyl)cyclopropyl]sulfonylphenoxy]propan-2-ol Chemical compound BrC=1C(=C(C=CC=1)S(=O)(=O)N1CCC2(C[C@@H](CO2)NC[C@@H](COC2=CC(=CC=C2)S(=O)(=O)C2(CC2)CO)O)CC1)C SQAORIPHBFMSKS-VXKWHMMOSA-N 0.000 description 1
- OAEHFKOVRLXYPB-SFTDATJTSA-N (2S)-1-[[(3S)-8-(3-bromo-4-methoxyphenyl)sulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]-3-[3-[1-(hydroxymethyl)cyclopropyl]sulfonylphenoxy]propan-2-ol Chemical compound COC1=C(Br)C=C(C=C1)S(=O)(=O)N1CCC2(C[C@@H](CO2)NC[C@H](O)COC2=CC(=CC=C2)S(=O)(=O)C2(CO)CC2)CC1 OAEHFKOVRLXYPB-SFTDATJTSA-N 0.000 description 1
- QPBQFEJPWYJSAG-VXKWHMMOSA-N (2S)-1-[[(3S)-8-(4-bromo-3-methylphenyl)sulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]-3-[3-[1-(hydroxymethyl)cyclopropyl]sulfonylphenoxy]propan-2-ol Chemical compound CC1=C(Br)C=CC(=C1)S(=O)(=O)N1CCC2(C[C@@H](CO2)NC[C@H](O)COC2=CC(=CC=C2)S(=O)(=O)C2(CO)CC2)CC1 QPBQFEJPWYJSAG-VXKWHMMOSA-N 0.000 description 1
- KLAPZKZSNVVREN-SFTDATJTSA-N (2S)-1-[[(3S)-8-(5-bromopyridin-3-yl)sulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]-3-[3-[1-(hydroxymethyl)cyclopropyl]sulfonylphenoxy]propan-2-ol Chemical compound BrC=1C=C(C=NC=1)S(=O)(=O)N1CCC2(C[C@@H](CO2)NC[C@@H](COC2=CC(=CC=C2)S(=O)(=O)C2(CC2)CO)O)CC1 KLAPZKZSNVVREN-SFTDATJTSA-N 0.000 description 1
- XZFHZWDHAUCDSL-GOTSBHOMSA-N (2S)-1-[[(3S)-8-[(1,8-dimethyl-2,3-dihydropyrido[2,3-b][1,4]oxazin-7-yl)sulfonyl]-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]-3-[3-[1-(hydroxymethyl)cyclopropyl]sulfonylphenoxy]propan-2-ol Chemical compound CN1C2=C(OCC1)N=CC(=C2C)S(=O)(=O)N1CCC2(C[C@@H](CO2)NC[C@@H](COC2=CC(=CC=C2)S(=O)(=O)C2(CC2)CO)O)CC1 XZFHZWDHAUCDSL-GOTSBHOMSA-N 0.000 description 1
- VZLLUIYABKBTJD-CONSDPRKSA-N (2S)-1-[[(3S)-8-[3-[4-(1-amino-2-methylpropan-2-yl)phenyl]phenyl]sulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]-3-[3-[1-(hydroxymethyl)cyclopropyl]sulfonylphenoxy]propan-2-ol Chemical compound NCC(C)(C)C1=CC=C(C=C1)C1=CC(=CC=C1)S(=O)(=O)N1CCC2(C[C@@H](CO2)NC[C@@H](COC2=CC(=CC=C2)S(=O)(=O)C2(CC2)CO)O)CC1 VZLLUIYABKBTJD-CONSDPRKSA-N 0.000 description 1
- HXKANHZDNNIVBW-NSOVKSMOSA-N (2S)-1-[[(3S)-8-[3-[4-(1-aminocyclopropyl)phenyl]-4-fluorophenyl]sulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]-3-[3-[1-(hydroxymethyl)cyclopropyl]sulfonylphenoxy]propan-2-ol Chemical compound NC1(CC1)C1=CC=C(C=C1)C1=CC(=CC=C1F)S(=O)(=O)N1CCC2(C[C@@H](CO2)NC[C@@H](COC2=CC(=CC=C2)S(=O)(=O)C2(CC2)CO)O)CC1 HXKANHZDNNIVBW-NSOVKSMOSA-N 0.000 description 1
- XVQIAXXIDIEWSB-SVBPBHIXSA-N (2S)-1-[[(3S)-8-[3-[4-(1-aminocyclopropyl)phenyl]-4-methoxyphenyl]sulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]-3-[3-(1,1-difluoro-2-hydroxyethyl)sulfonylphenoxy]propan-2-ol Chemical compound NC1(CC1)C1=CC=C(C=C1)C1=CC(=CC=C1OC)S(=O)(=O)N1CCC2(C[C@@H](CO2)NC[C@@H](COC2=CC(=CC=C2)S(=O)(=O)C(CO)(F)F)O)CC1 XVQIAXXIDIEWSB-SVBPBHIXSA-N 0.000 description 1
- DGRIYGWZULRJSB-KYJUHHDHSA-N (2S)-1-[[(3S)-8-[3-[4-(1-aminocyclopropyl)phenyl]phenyl]sulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]-3-[3-[1-(hydroxymethyl)cyclopropyl]sulfonylphenoxy]propan-2-ol Chemical compound NC1(CC1)C1=CC=C(C=C1)C1=CC(=CC=C1)S(=O)(=O)N1CCC2(C[C@@H](CO2)NC[C@@H](COC2=CC(=CC=C2)S(=O)(=O)C2(CC2)CO)O)CC1 DGRIYGWZULRJSB-KYJUHHDHSA-N 0.000 description 1
- OTTAXHQDRZQBSM-NSOVKSMOSA-N (2S)-1-[[(3S)-8-[3-[4-(2-aminoethyl)phenyl]phenyl]sulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]-3-[3-(1,1-difluoro-2-hydroxyethyl)sulfonylphenoxy]propan-2-ol Chemical compound NCCC1=CC=C(C=C1)C1=CC(=CC=C1)S(=O)(=O)N1CCC2(C[C@@H](CO2)NC[C@H](O)COC2=CC(=CC=C2)S(=O)(=O)C(F)(F)CO)CC1 OTTAXHQDRZQBSM-NSOVKSMOSA-N 0.000 description 1
- MBIXCUIOHLJBGG-KYJUHHDHSA-N (2S)-1-[[(3S)-8-[3-[4-(2-aminoethyl)phenyl]phenyl]sulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]-3-[3-[1-(hydroxymethyl)cyclopropyl]sulfonylphenoxy]propan-2-ol Chemical compound NCCC1=CC=C(C=C1)C1=CC(=CC=C1)S(=O)(=O)N1CCC2(C[C@@H](CO2)NC[C@H](O)COC2=CC(=CC=C2)S(=O)(=O)C2(CO)CC2)CC1 MBIXCUIOHLJBGG-KYJUHHDHSA-N 0.000 description 1
- BKQRNIHWLDUDNC-NSOVKSMOSA-N (2S)-1-[[(3S)-8-[3-[4-(aminomethyl)-3-fluorophenyl]phenyl]sulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]-3-[3-[1-(hydroxymethyl)cyclopropyl]sulfonylphenoxy]propan-2-ol Chemical compound NCC1=C(C=C(C=C1)C1=CC(=CC=C1)S(=O)(=O)N1CCC2(C[C@@H](CO2)NC[C@@H](COC2=CC(=CC=C2)S(=O)(=O)C2(CC2)CO)O)CC1)F BKQRNIHWLDUDNC-NSOVKSMOSA-N 0.000 description 1
- QRZOTKOCYQZEMQ-VMPREFPWSA-N (2S)-1-[[(3S)-8-[3-[4-(aminomethyl)phenyl]-2-methylphenyl]sulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]-3-[3-[1-(hydroxymethyl)cyclopropyl]sulfonylphenoxy]propan-2-ol Chemical compound NCC1=CC=C(C=C1)C1=C(C(=CC=C1)S(=O)(=O)N1CCC2(C[C@@H](CO2)NC[C@@H](COC2=CC(=CC=C2)S(=O)(=O)C2(CC2)CO)O)CC1)C QRZOTKOCYQZEMQ-VMPREFPWSA-N 0.000 description 1
- FSKYBDXZEKLIGG-SVBPBHIXSA-N (2S)-1-[[(3S)-8-[3-[4-(aminomethyl)phenyl]-4-fluorophenyl]sulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]-3-[3-[1-(hydroxymethyl)cyclopropyl]sulfonylphenoxy]propan-2-ol Chemical compound NCC1=CC=C(C=C1)C1=CC(=CC=C1F)S(=O)(=O)N1CCC2(C[C@@H](CO2)NC[C@@H](COC2=CC(=CC=C2)S(=O)(=O)C2(CC2)CO)O)CC1 FSKYBDXZEKLIGG-SVBPBHIXSA-N 0.000 description 1
- RUWRSXRXXCQTGS-VMPREFPWSA-N (2S)-1-[[(3S)-8-[3-[4-(aminomethyl)phenyl]phenyl]sulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]-3-[3-[1-(hydroxymethyl)cyclopropyl]sulfonylphenoxy]propan-2-ol Chemical compound NCC1=CC=C(C=C1)C1=CC(=CC=C1)S(=O)(=O)N1CCC2(C[C@@H](CO2)NC[C@H](O)COC2=CC(=CC=C2)S(=O)(=O)C2(CO)CC2)CC1 RUWRSXRXXCQTGS-VMPREFPWSA-N 0.000 description 1
- FEJYSMWXFZDMFI-ACHIHNKUSA-N (2S)-1-[[(3S)-8-[3-[4-(azetidin-1-ylmethyl)phenyl]phenyl]sulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]-3-[3-[1-(hydroxymethyl)cyclopropyl]sulfonylphenoxy]propan-2-ol Chemical compound OCC1(CC1)S(=O)(=O)C1=CC=CC(OC[C@@H](O)CN[C@@H]2COC3(C2)CCN(CC3)S(=O)(=O)C2=CC=CC(=C2)C2=CC=C(CN3CCC3)C=C2)=C1 FEJYSMWXFZDMFI-ACHIHNKUSA-N 0.000 description 1
- CZGOTIBAUNXPDM-LQJZCPKCSA-N (2S)-1-[[(3S)-8-[3-[4-(butylaminomethyl)phenyl]phenyl]sulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]-3-[3-[1-(hydroxymethyl)cyclopropyl]sulfonylphenoxy]propan-2-ol Chemical compound CCCCNCC1=CC=C(C=C1)C1=CC(=CC=C1)S(=O)(=O)N1CCC2(C[C@@H](CO2)NC[C@H](O)COC2=CC(=CC=C2)S(=O)(=O)C2(CO)CC2)CC1 CZGOTIBAUNXPDM-LQJZCPKCSA-N 0.000 description 1
- QCSNKQSIUIMGFB-ACHIHNKUSA-N (2S)-1-[[(3S)-8-[3-[4-[(tert-butylamino)methyl]phenyl]phenyl]sulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]-3-[3-[1-(hydroxymethyl)cyclopropyl]sulfonylphenoxy]propan-2-ol Chemical compound CC(C)(C)NCC1=CC=C(C=C1)C1=CC(=CC=C1)S(=O)(=O)N1CCC2(C[C@@H](CO2)NC[C@H](O)COC2=CC(=CC=C2)S(=O)(=O)C2(CO)CC2)CC1 QCSNKQSIUIMGFB-ACHIHNKUSA-N 0.000 description 1
- HJLKDKOTEPIMQY-ACHIHNKUSA-N (2S)-1-[[(3S)-8-[5-[4-(1-amino-2-methylpropan-2-yl)phenyl]-2-ethoxyphenyl]sulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]-3-[3-[1-(hydroxymethyl)cyclopropyl]sulfonylphenoxy]propan-2-ol Chemical compound NCC(C)(C)C1=CC=C(C=C1)C1=CC(=C(C=C1)OCC)S(=O)(=O)N1CCC2(C[C@@H](CO2)NC[C@@H](COC2=CC(=CC=C2)S(=O)(=O)C2(CC2)CO)O)CC1 HJLKDKOTEPIMQY-ACHIHNKUSA-N 0.000 description 1
- FGYZEYVCZHNCAD-CONSDPRKSA-N (2S)-1-[[(3S)-8-[5-[4-(2-aminopropan-2-yl)phenyl]-2-ethoxyphenyl]sulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]-3-[3-[1-(hydroxymethyl)cyclopropyl]sulfonylphenoxy]propan-2-ol Chemical compound CCOC1=C(C=C(C=C1)C1=CC=C(C=C1)C(C)(C)N)S(=O)(=O)N1CCC2(C[C@@H](CO2)NC[C@H](O)COC2=CC(=CC=C2)S(=O)(=O)C2(CO)CC2)CC1 FGYZEYVCZHNCAD-CONSDPRKSA-N 0.000 description 1
- ZOUMUQSUBBTKJK-VMPREFPWSA-N (2S)-1-[[(3S)-8-[5-[4-(aminomethyl)-3-fluorophenyl]-2-ethoxyphenyl]sulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]-3-[3-[1-(hydroxymethyl)cyclopropyl]sulfonylphenoxy]propan-2-ol Chemical compound CCOc1ccc(cc1S(=O)(=O)N1CCC2(C[C@@H](CO2)NC[C@H](O)COc2cccc(c2)S(=O)(=O)C2(CO)CC2)CC1)-c1ccc(CN)c(F)c1 ZOUMUQSUBBTKJK-VMPREFPWSA-N 0.000 description 1
- MWSDJOPJPPASIH-KYJUHHDHSA-N (2S)-1-[[(3S)-8-[5-[4-(aminomethyl)phenyl]-2-propan-2-yloxyphenyl]sulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]-3-(3-cyclopropylsulfonylphenoxy)propan-2-ol Chemical compound NCC1=CC=C(C=C1)C1=CC(=C(C=C1)OC(C)C)S(=O)(=O)N1CCC2(C[C@@H](CO2)NC[C@@H](COC2=CC(=CC=C2)S(=O)(=O)C2CC2)O)CC1 MWSDJOPJPPASIH-KYJUHHDHSA-N 0.000 description 1
- UIKIKDMMQBRBCH-LBAQZLPGSA-N (2S)-1-[[8-(1-benzofuran-2-ylsulfonyl)-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]-3-(3-methylsulfonylphenoxy)propan-2-ol Chemical compound O1C(=CC2=C1C=CC=C2)S(=O)(=O)N1CCC2(CC(CO2)NC[C@@H](COC2=CC(=CC=C2)S(=O)(=O)C)O)CC1 UIKIKDMMQBRBCH-LBAQZLPGSA-N 0.000 description 1
- IWEUQEHUVOGLMR-LBAQZLPGSA-N (2S)-1-[[8-(1-benzofuran-5-ylsulfonyl)-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]-3-(3-methylsulfonylphenoxy)propan-2-ol Chemical compound O1C=CC2=C1C=CC(=C2)S(=O)(=O)N1CCC2(CC(CO2)NC[C@@H](COC2=CC(=CC=C2)S(=O)(=O)C)O)CC1 IWEUQEHUVOGLMR-LBAQZLPGSA-N 0.000 description 1
- ZPISMZFHLHKRCV-ANYOKISRSA-N (2S)-1-[[8-(1-ethyl-5-methylpyrazol-4-yl)sulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]-3-(3-methylsulfonylphenoxy)propan-2-ol Chemical compound C(C)N1N=CC(=C1C)S(=O)(=O)N1CCC2(CC(CO2)NC[C@@H](COC2=CC(=CC=C2)S(=O)(=O)C)O)CC1 ZPISMZFHLHKRCV-ANYOKISRSA-N 0.000 description 1
- SJNJREUREQLUOI-ANYOKISRSA-N (2S)-1-[[8-(1H-indazol-5-ylsulfonyl)-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]-3-(3-methylsulfonylphenoxy)propan-2-ol Chemical compound N1N=CC2=CC(=CC=C12)S(=O)(=O)N1CCC2(CC(CO2)NC[C@@H](COC2=CC(=CC=C2)S(=O)(=O)C)O)CC1 SJNJREUREQLUOI-ANYOKISRSA-N 0.000 description 1
- QBYCQUKVFQQBNX-LBAQZLPGSA-N (2S)-1-[[8-(1H-indol-5-ylsulfonyl)-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]-3-(3-methylsulfonylphenoxy)propan-2-ol Chemical compound N1C=CC2=CC(=CC=C12)S(=O)(=O)N1CCC2(CC(CO2)NC[C@@H](COC2=CC(=CC=C2)S(=O)(=O)C)O)CC1 QBYCQUKVFQQBNX-LBAQZLPGSA-N 0.000 description 1
- DUVQHZAYCRDMPO-LBAQZLPGSA-N (2S)-1-[[8-(2,3-dihydro-1-benzofuran-5-ylsulfonyl)-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]-3-(3-methylsulfonylphenoxy)propan-2-ol Chemical compound O1CCC2=C1C=CC(=C2)S(=O)(=O)N1CCC2(CC(CO2)NC[C@@H](COC2=CC(=CC=C2)S(=O)(=O)C)O)CC1 DUVQHZAYCRDMPO-LBAQZLPGSA-N 0.000 description 1
- OGNAUUVHRAKJPR-ANYOKISRSA-N (2S)-1-[[8-(3-bromophenyl)sulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]-3-(3-methylsulfonylphenoxy)propan-2-ol Chemical compound BrC=1C=C(C=CC=1)S(=O)(=O)N1CCC2(CC(CO2)NC[C@@H](COC2=CC(=CC=C2)S(=O)(=O)C)O)CC1 OGNAUUVHRAKJPR-ANYOKISRSA-N 0.000 description 1
- LWLAJXQHUBFQPA-ANYOKISRSA-N (2S)-1-[[8-(3-chlorophenyl)sulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]-3-(3-methylsulfonylphenoxy)propan-2-ol Chemical compound ClC=1C=C(C=CC=1)S(=O)(=O)N1CCC2(CC(CO2)NC[C@@H](COC2=CC(=CC=C2)S(=O)(=O)C)O)CC1 LWLAJXQHUBFQPA-ANYOKISRSA-N 0.000 description 1
- XQZLYPMRDBIENL-ANYOKISRSA-N (2S)-1-[[8-(3-fluorophenyl)sulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]-3-(3-methylsulfonylphenoxy)propan-2-ol Chemical compound FC=1C=C(C=CC=1)S(=O)(=O)N1CCC2(CC(CO2)NC[C@@H](COC2=CC(=CC=C2)S(=O)(=O)C)O)CC1 XQZLYPMRDBIENL-ANYOKISRSA-N 0.000 description 1
- XFWUIZALJSHWQU-LBAQZLPGSA-N (2S)-1-[[8-(3-methylphenyl)sulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]-3-(3-methylsulfonylphenoxy)propan-2-ol Chemical compound CS(=O)(=O)C=1C=C(OC[C@H](CNC2COC3(C2)CCN(CC3)S(=O)(=O)C=2C=C(C=CC=2)C)O)C=CC=1 XFWUIZALJSHWQU-LBAQZLPGSA-N 0.000 description 1
- UWSGHEIGFKKXNB-GGYWPGCISA-N (2S)-1-[[8-(3H-benzimidazol-5-ylsulfonyl)-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]-3-(3-methylsulfonylphenoxy)propan-2-ol Chemical compound N1C=NC2=C1C=CC(=C2)S(=O)(=O)N1CCC2(CC(CO2)NC[C@@H](COC2=CC(=CC=C2)S(=O)(=O)C)O)CC1 UWSGHEIGFKKXNB-GGYWPGCISA-N 0.000 description 1
- VAMKQEICVUWJMR-KEKNWZKVSA-N (2S)-1-[[8-(5-chloronaphthalen-2-yl)sulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]-3-(3-methylsulfonylphenoxy)propan-2-ol Chemical compound ClC1=C2C=CC(=CC2=CC=C1)S(=O)(=O)N1CCC2(CC(CO2)NC[C@@H](COC2=CC(=CC=C2)S(=O)(=O)C)O)CC1 VAMKQEICVUWJMR-KEKNWZKVSA-N 0.000 description 1
- KCWKTASKNKHZEB-CGAIIQECSA-N (2S)-1-[[8-(6-chloronaphthalen-2-yl)sulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]-3-(3-methylsulfonylphenoxy)propan-2-ol Chemical compound ClC=1C=C2C=CC(=CC2=CC=1)S(=O)(=O)N1CCC2(CC(CO2)NC[C@@H](COC2=CC(=CC=C2)S(=O)(=O)C)O)CC1 KCWKTASKNKHZEB-CGAIIQECSA-N 0.000 description 1
- RVKZTACJBPCPPD-GGYWPGCISA-N (2S)-1-[[8-[(3,5-dimethyl-1,2-oxazol-4-yl)sulfonyl]-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]-3-(3-methylsulfonylphenoxy)propan-2-ol Chemical compound CC1=NOC(=C1S(=O)(=O)N1CCC2(CC(CO2)NC[C@@H](COC2=CC(=CC=C2)S(=O)(=O)C)O)CC1)C RVKZTACJBPCPPD-GGYWPGCISA-N 0.000 description 1
- JKOCVCSGEXOPMS-DJNXLDHESA-N (2S)-1-[[8-[(4-chloro-2,1,3-benzoxadiazol-7-yl)sulfonyl]-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]-3-(3-methylsulfonylphenoxy)propan-2-ol Chemical compound ClC1=CC=C(C=2C1=NON=2)S(=O)(=O)N1CCC2(CC(CO2)NC[C@@H](COC2=CC(=CC=C2)S(=O)(=O)C)O)CC1 JKOCVCSGEXOPMS-DJNXLDHESA-N 0.000 description 1
- QIOSCNYSNQCKFH-LBAQZLPGSA-N (2S)-1-[[8-[(4-methyl-2,3-dihydro-1,4-benzoxazin-6-yl)sulfonyl]-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]-3-(3-methylsulfonylphenoxy)propan-2-ol Chemical compound CN1C2=C(OCC1)C=CC(=C2)S(=O)(=O)N1CCC2(CC(CO2)NC[C@@H](COC2=CC(=CC=C2)S(=O)(=O)C)O)CC1 QIOSCNYSNQCKFH-LBAQZLPGSA-N 0.000 description 1
- MEJIKIAPBJUAOG-CGAIIQECSA-N (2S)-1-[[8-[3-(6-aminopyridin-3-yl)phenyl]sulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]-3-(3-methylsulfonylphenoxy)propan-2-ol Chemical compound NC1=CC=C(C=N1)C=1C=C(C=CC=1)S(=O)(=O)N1CCC2(CC(CO2)NC[C@@H](COC2=CC(=CC=C2)S(=O)(=O)C)O)CC1 MEJIKIAPBJUAOG-CGAIIQECSA-N 0.000 description 1
- ZVUAQTHPGQDGEF-GEVKEYJPSA-N (2S)-1-[[8-[3-[4-(aminomethyl)phenyl]phenyl]sulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]-3-(3-methylsulfonylphenoxy)propan-2-ol Chemical compound NCC1=CC=C(C=C1)C1=CC(=CC=C1)S(=O)(=O)N1CCC2(CC(CO2)NC[C@@H](COC2=CC(=CC=C2)S(=O)(=O)C)O)CC1 ZVUAQTHPGQDGEF-GEVKEYJPSA-N 0.000 description 1
- QGANPEGIUQBWQQ-FLDQDSGZSA-N (2S)-1-[[8-[3-[4-[(2-methylpropylamino)methyl]phenyl]phenyl]sulfonyl-1-oxa-8-azaspiro[4.5]decan-3-yl]amino]-3-(3-methylsulfonylphenoxy)propan-2-ol Chemical compound C(C(C)C)NCC1=CC=C(C=C1)C1=CC(=CC=C1)S(=O)(=O)N1CCC2(CC(CO2)NC[C@@H](COC2=CC(=CC=C2)S(=O)(=O)C)O)CC1 QGANPEGIUQBWQQ-FLDQDSGZSA-N 0.000 description 1
- ALUKSHASDNTFSH-LURJTMIESA-N (2S)-2-[(3-bromo-2-fluorophenoxy)methyl]oxirane Chemical compound BrC=1C(=C(OC[C@H]2OC2)C=CC=1)F ALUKSHASDNTFSH-LURJTMIESA-N 0.000 description 1
- VDXYMZKYJKYJSO-LLVKDONJSA-N (2S)-2-[(3-cyclobutylsulfonylphenoxy)methyl]oxirane Chemical compound O=S(=O)(C1CCC1)c1cccc(OC[C@@H]2CO2)c1 VDXYMZKYJKYJSO-LLVKDONJSA-N 0.000 description 1
- SZNCIIOPNWNGSU-SNVBAGLBSA-N (2S)-2-[(3-ethylsulfonylphenoxy)methyl]oxirane Chemical compound C(C)S(=O)(=O)C=1C=C(OC[C@H]2OC2)C=CC=1 SZNCIIOPNWNGSU-SNVBAGLBSA-N 0.000 description 1
- WYAWLAKCAZZMNB-LLVKDONJSA-N (2S)-2-[(3-propan-2-ylsulfonylphenoxy)methyl]oxirane Chemical compound C(C)(C)S(=O)(=O)C=1C=C(OC[C@H]2OC2)C=CC=1 WYAWLAKCAZZMNB-LLVKDONJSA-N 0.000 description 1
- GANYMHLIFACVST-LLVKDONJSA-N (2S)-2-[(3-propylsulfonylphenoxy)methyl]oxirane Chemical compound CCCS(=O)(=O)c1cccc(OC[C@@H]2CO2)c1 GANYMHLIFACVST-LLVKDONJSA-N 0.000 description 1
- LPQCQKTWSJSYTE-LHIURRSHSA-N (2S)-2-[[3-(1-fluoroethylsulfonyl)phenoxy]methyl]oxirane Chemical compound CC(F)S(=O)(=O)c1cccc(OC[C@@H]2CO2)c1 LPQCQKTWSJSYTE-LHIURRSHSA-N 0.000 description 1
- PQNVHTXMSSBHOZ-GFCCVEGCSA-N (2S)-2-[[3-(2-methylpropylsulfonyl)phenoxy]methyl]oxirane Chemical compound CC(C)CS(=O)(=O)c1cccc(OC[C@@H]2CO2)c1 PQNVHTXMSSBHOZ-GFCCVEGCSA-N 0.000 description 1
- XEONMRARRXXGKC-SNVBAGLBSA-N (2S)-2-[[3-(3,3,3-trifluoropropylsulfonyl)phenoxy]methyl]oxirane Chemical compound FC(F)(F)CCS(=O)(=O)c1cccc(OC[C@@H]2CO2)c1 XEONMRARRXXGKC-SNVBAGLBSA-N 0.000 description 1
- AKHGFOFXKISPEW-GFCCVEGCSA-N (2S)-2-[[3-(3-methoxypropylsulfonyl)phenoxy]methyl]oxirane Chemical compound COCCCS(=O)(=O)c1cccc(OC[C@@H]2CO2)c1 AKHGFOFXKISPEW-GFCCVEGCSA-N 0.000 description 1
- XSXXVXZJKAFSFW-CYBMUJFWSA-N (2S)-2-[[3-(3-methylbutylsulfonyl)phenoxy]methyl]oxirane Chemical compound CC(C)CCS(=O)(=O)c1cccc(OC[C@@H]2CO2)c1 XSXXVXZJKAFSFW-CYBMUJFWSA-N 0.000 description 1
- UHXSOPGSHFBIFK-SNVBAGLBSA-N (2S)-2-[[3-(methoxymethylsulfonyl)phenoxy]methyl]oxirane Chemical compound COCS(=O)(=O)c1cccc(OC[C@@H]2CO2)c1 UHXSOPGSHFBIFK-SNVBAGLBSA-N 0.000 description 1
- UCVRDTAYJVXXLQ-HCCKASOXSA-N (2S)-2-[[3-[(2,2-difluorocyclopropyl)methylsulfonyl]phenoxy]methyl]oxirane Chemical compound FC1(F)CC1CS(=O)(=O)c1cccc(OC[C@@H]2CO2)c1 UCVRDTAYJVXXLQ-HCCKASOXSA-N 0.000 description 1
- GBZNGWSRBGPZIY-KCJUWKMLSA-N (2S,3S)-2,3-dihydroxy-2-(4-methylphenyl)butanedioic acid Chemical compound C1(=CC=C(C=C1)[C@](C(=O)O)(O)[C@H](O)C(=O)O)C GBZNGWSRBGPZIY-KCJUWKMLSA-N 0.000 description 1
- VIPJDVWBJSFNLV-SECBINFHSA-N (2s)-2-[(3-iodophenoxy)methyl]oxirane Chemical compound IC1=CC=CC(OC[C@H]2OC2)=C1 VIPJDVWBJSFNLV-SECBINFHSA-N 0.000 description 1
- NSFIAKFOCAEBER-QZTJIDSGSA-N (2s,3s)-2,3-dihydroxy-2,3-bis(4-methylphenyl)butanedioic acid Chemical compound C1=CC(C)=CC=C1[C@@](O)(C(O)=O)[C@](O)(C(O)=O)C1=CC=C(C)C=C1 NSFIAKFOCAEBER-QZTJIDSGSA-N 0.000 description 1
- YDBORVDWDAEVMA-LURJTMIESA-N (3S)-1,3-dimethyl-2,3-dihydropyrido[2,3-b][1,4]oxazine-7-sulfonyl chloride Chemical compound C[C@H]1CN(C)c2cc(cnc2O1)S(Cl)(=O)=O YDBORVDWDAEVMA-LURJTMIESA-N 0.000 description 1
- LCIHOMYWNFSJRP-ZETCQYMHSA-N (3S)-1-oxa-8-azaspiro[4.5]decan-3-amine Chemical compound N[C@@H]1COC2(C1)CCNCC2 LCIHOMYWNFSJRP-ZETCQYMHSA-N 0.000 description 1
- PLIVQLZAQGVJJP-LURJTMIESA-N (3S)-7-bromo-1,3-dimethyl-2,3-dihydropyrido[2,3-b][1,4]oxazine Chemical compound BrC1=CC2=C(O[C@H](CN2C)C)N=C1 PLIVQLZAQGVJJP-LURJTMIESA-N 0.000 description 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- 125000004607 1,2,3,4-tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- PMHPDAIJCUTMDS-UHFFFAOYSA-N 1,3,3-trimethyl-2H-pyrido[2,3-b][1,4]oxazine-7-sulfonyl chloride Chemical compound CN1CC(C)(C)Oc2ncc(cc12)S(Cl)(=O)=O PMHPDAIJCUTMDS-UHFFFAOYSA-N 0.000 description 1
- MENHXVNCWVKFRA-UHFFFAOYSA-N 1,4-oxazin-2-one Chemical compound O=C1C=NC=CO1 MENHXVNCWVKFRA-UHFFFAOYSA-N 0.000 description 1
- FMFZIILVFRCLFO-UHFFFAOYSA-N 1,6-dimethyl-2,3-dihydropyrido[2,3-b][1,4]oxazine-7-sulfonyl chloride Chemical compound CN1CCOc2nc(C)c(cc12)S(Cl)(=O)=O FMFZIILVFRCLFO-UHFFFAOYSA-N 0.000 description 1
- FTCGCWYFOQVGSE-UHFFFAOYSA-N 1,8-dimethyl-2,3-dihydropyrido[2,3-b][1,4]oxazine-7-sulfonyl chloride Chemical compound CN1CCOc2ncc(c(C)c12)S(Cl)(=O)=O FTCGCWYFOQVGSE-UHFFFAOYSA-N 0.000 description 1
- GYFLGNYMAQZIQQ-UHFFFAOYSA-N 1-[3-[1-(hydroxymethyl)cyclopropyl]sulfonylphenoxy]propan-2-ol Chemical compound OCC1(CC1)S(=O)(=O)C=1C=C(OCC(C)O)C=CC=1 GYFLGNYMAQZIQQ-UHFFFAOYSA-N 0.000 description 1
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 1
- XVNQVSGOIUYOPB-UHFFFAOYSA-N 1-bromo-3-fluoro-5-methoxybenzene Chemical compound COC1=CC(F)=CC(Br)=C1 XVNQVSGOIUYOPB-UHFFFAOYSA-N 0.000 description 1
- HWYIRYBBKDTTST-UHFFFAOYSA-N 1-ethoxynaphthalene-2-sulfonyl chloride Chemical compound C1=CC=C2C(OCC)=C(S(Cl)(=O)=O)C=CC2=C1 HWYIRYBBKDTTST-UHFFFAOYSA-N 0.000 description 1
- JVASNHOIZARHQW-UHFFFAOYSA-N 1-ethyl-2,3-dihydropyrido[2,3-b][1,4]oxazine-7-sulfonyl chloride Chemical compound CCN1CCOc2ncc(cc12)S(Cl)(=O)=O JVASNHOIZARHQW-UHFFFAOYSA-N 0.000 description 1
- PQNQOHDLTYFBHE-UHFFFAOYSA-N 1-ethyl-2h-quinoline Chemical compound C1=CC=C2N(CC)CC=CC2=C1 PQNQOHDLTYFBHE-UHFFFAOYSA-N 0.000 description 1
- PVXLIOIISUUKOQ-VXKWHMMOSA-N 1-ethyl-3-[[(3S)-3-[[(2S)-2-hydroxy-3-(3-methylsulfonylphenoxy)propyl]amino]-1-oxa-8-azaspiro[4.5]decan-8-yl]sulfonyl]quinolin-4-one Chemical compound CCN1C=C(C(=O)C2=C1C=CC=C2)S(=O)(=O)N1CCC2(C[C@@H](CO2)NC[C@H](O)COC2=CC(=CC=C2)S(C)(=O)=O)CC1 PVXLIOIISUUKOQ-VXKWHMMOSA-N 0.000 description 1
- DKWDDXCZKFLKQJ-UHFFFAOYSA-N 1-ethylquinolin-4-one Chemical compound C1=CC=C2N(CC)C=CC(=O)C2=C1 DKWDDXCZKFLKQJ-UHFFFAOYSA-N 0.000 description 1
- 125000006420 1-fluorocyclopropyl group Chemical group [H]C1([H])C([H])([H])C1(F)* 0.000 description 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
- LJVAVOYDALPTQO-UHFFFAOYSA-N 1-methyl-4-oxoquinoline-3-sulfonyl chloride Chemical compound C1=CC=C2N(C)C=C(S(Cl)(=O)=O)C(=O)C2=C1 LJVAVOYDALPTQO-UHFFFAOYSA-N 0.000 description 1
- CTBJXZQZLJQLOW-UHFFFAOYSA-N 1-methylspiro[2H-pyrido[2,3-b][1,4]oxazine-3,1'-cyclopropane]-7-sulfonyl chloride Chemical compound CN1CC2(CC2)Oc2ncc(cc12)S(Cl)(=O)=O CTBJXZQZLJQLOW-UHFFFAOYSA-N 0.000 description 1
- LCIHOMYWNFSJRP-UHFFFAOYSA-N 1-oxa-8-azaspiro[4.5]decan-3-amine Chemical compound C1C(N)COC21CCNCC2 LCIHOMYWNFSJRP-UHFFFAOYSA-N 0.000 description 1
- JQNSUWHWLBLHQL-UHFFFAOYSA-N 1-oxa-8-azaspiro[4.5]decan-3-ol Chemical compound C1C(O)COC21CCNCC2 JQNSUWHWLBLHQL-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- QOXHOUVXCHQTDM-UHFFFAOYSA-N 1H-pyrazolo[4,3-b]pyridine-6-sulfonyl chloride Chemical compound ClS(=O)(=O)c1cnc2cn[nH]c2c1 QOXHOUVXCHQTDM-UHFFFAOYSA-N 0.000 description 1
- PJXABYMNVZGIPN-UHFFFAOYSA-N 1h-pyrido[2,3-b][1,4]oxazine Chemical compound C1=CC=C2NC=COC2=N1 PJXABYMNVZGIPN-UHFFFAOYSA-N 0.000 description 1
- CNZIHLRMHLLIJQ-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine-3-sulfonyl chloride Chemical compound C1=CC=C2C(S(=O)(=O)Cl)=CNC2=N1 CNZIHLRMHLLIJQ-UHFFFAOYSA-N 0.000 description 1
- XWIYUCRMWCHYJR-UHFFFAOYSA-N 1h-pyrrolo[3,2-b]pyridine Chemical compound C1=CC=C2NC=CC2=N1 XWIYUCRMWCHYJR-UHFFFAOYSA-N 0.000 description 1
- LFEIPPVXDBVWCZ-UHFFFAOYSA-N 1h-pyrrolo[3,2-b]pyridine-6-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CN=C2C=CNC2=C1 LFEIPPVXDBVWCZ-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- OCRAOACZGIOARL-ZVAWYAOSSA-N 2-(2-amino-1,3-thiazol-4-yl)-1-[3-[[(2S)-2-hydroxy-3-(3-methylsulfonylphenoxy)propyl]amino]-1-oxa-8-azaspiro[4.5]decan-8-yl]ethanone Chemical compound CS(=O)(=O)C1=CC=CC(OC[C@@H](O)CNC2COC3(C2)CCN(CC3)C(=O)CC2=CSC(N)=N2)=C1 OCRAOACZGIOARL-ZVAWYAOSSA-N 0.000 description 1
- SKEHXTOXRYJBRL-UHFFFAOYSA-N 2-(3-hydroxyphenyl)sulfanylacetamide Chemical compound NC(=O)CSC1=CC=CC(O)=C1 SKEHXTOXRYJBRL-UHFFFAOYSA-N 0.000 description 1
- FEGLGESJSXPNNP-UHFFFAOYSA-N 2-(3-hydroxyphenyl)sulfonylacetamide Chemical compound OC=1C=C(C=CC=1)S(=O)(=O)CC(=O)N FEGLGESJSXPNNP-UHFFFAOYSA-N 0.000 description 1
- XSZFMIXMRYOGOQ-UHFFFAOYSA-N 2-(3-hydroxyphenyl)sulfonylacetonitrile Chemical compound Oc1cccc(c1)S(=O)(=O)CC#N XSZFMIXMRYOGOQ-UHFFFAOYSA-N 0.000 description 1
- SGVQMKDQDTWFEM-UHFFFAOYSA-N 2-(diethylamino)ethyl 4-(chloroamino)benzoate Chemical compound CCN(CC)CCOC(=O)C1=CC=C(NCl)C=C1 SGVQMKDQDTWFEM-UHFFFAOYSA-N 0.000 description 1
- NYJLGWFZULSFLG-SECBINFHSA-N 2-[3-[[(2S)-oxiran-2-yl]methoxy]phenyl]sulfonylacetamide Chemical compound O1[C@@H](C1)COC=1C=C(C=CC=1)S(=O)(=O)CC(=O)N NYJLGWFZULSFLG-SECBINFHSA-N 0.000 description 1
- APCRIZAPUPTZME-SNVBAGLBSA-N 2-[3-[[(2S)-oxiran-2-yl]methoxy]phenyl]sulfonylethanol Chemical compound O1[C@@H](C1)COC=1C=C(C=CC=1)S(=O)(=O)CCO APCRIZAPUPTZME-SNVBAGLBSA-N 0.000 description 1
- OQAOGBAMFWFEKY-SNVBAGLBSA-N 2-[3-fluoro-5-[[(2S)-oxiran-2-yl]methoxy]phenyl]sulfonylethanol Chemical compound OCCS(=O)(=O)c1cc(F)cc(OC[C@@H]2CO2)c1 OQAOGBAMFWFEKY-SNVBAGLBSA-N 0.000 description 1
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 description 1
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
- ZFFBIQMNKOJDJE-UHFFFAOYSA-N 2-bromo-1,2-diphenylethanone Chemical compound C=1C=CC=CC=1C(Br)C(=O)C1=CC=CC=C1 ZFFBIQMNKOJDJE-UHFFFAOYSA-N 0.000 description 1
- YOCIJWAHRAJQFT-UHFFFAOYSA-N 2-bromo-2-methylpropanoyl bromide Chemical compound CC(C)(Br)C(Br)=O YOCIJWAHRAJQFT-UHFFFAOYSA-N 0.000 description 1
- JUIKUQOUMZUFQT-UHFFFAOYSA-N 2-bromoacetamide Chemical compound NC(=O)CBr JUIKUQOUMZUFQT-UHFFFAOYSA-N 0.000 description 1
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 1
- NMTHIKAERJUHSH-UHFFFAOYSA-N 2-methoxy-n-[(4-phenylphenyl)methyl]ethanamine Chemical group C1=CC(CNCCOC)=CC=C1C1=CC=CC=C1 NMTHIKAERJUHSH-UHFFFAOYSA-N 0.000 description 1
- VAMPTSRWVXGXTE-LLVKDONJSA-N 2-methyl-2-[3-[[(2S)-oxiran-2-yl]methoxy]phenyl]sulfonylpropan-1-ol Chemical compound CC(CO)(C)S(=O)(=O)C1=CC(=CC=C1)OC[C@H]1OC1 VAMPTSRWVXGXTE-LLVKDONJSA-N 0.000 description 1
- JJUZKPZRBOWPAF-SNVBAGLBSA-N 2-methyl-2-[3-[[(2S)-oxiran-2-yl]methoxy]phenyl]sulfonylpropanamide Chemical compound CC(C)(C(N)=O)S(=O)(=O)c1cccc(OC[C@@H]2CO2)c1 JJUZKPZRBOWPAF-SNVBAGLBSA-N 0.000 description 1
- IIIOXYPRJHEIFR-UHFFFAOYSA-N 2-methyl-n-[(4-phenylphenyl)methyl]propan-1-amine Chemical group C1=CC(CNCC(C)C)=CC=C1C1=CC=CC=C1 IIIOXYPRJHEIFR-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000004819 2-methylbutylene group Chemical group [H]C([H])([H])C([H])(C([H])([H])[*:1])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- VFBYGEVTEDDDNO-UHFFFAOYSA-N 2-oxo-1,3-dihydropyrrolo[2,3-b]pyridine-5-sulfonyl chloride Chemical compound ClS(=O)(=O)c1cnc2NC(=O)Cc2c1 VFBYGEVTEDDDNO-UHFFFAOYSA-N 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- PZIFMWOUBFXICI-UHFFFAOYSA-N 3,4-dihydro-2H-pyrano[2,3-b]pyridine-6-sulfonyl chloride Chemical compound ClS(=O)(=O)c1cnc2OCCCc2c1 PZIFMWOUBFXICI-UHFFFAOYSA-N 0.000 description 1
- BPDQGTJNPPYEFJ-UHFFFAOYSA-N 3-(1-hydroxy-2-methylpropan-2-yl)sulfonylphenol Chemical compound OCC(C)(C)S(=O)(=O)C=1C=C(C=CC=1)O BPDQGTJNPPYEFJ-UHFFFAOYSA-N 0.000 description 1
- CMAQYLQZRJLQHR-UHFFFAOYSA-N 3-(3-methoxyphenyl)sulfonylcyclobutan-1-ol Chemical compound COC=1C=C(C=CC=1)S(=O)(=O)C1CC(C1)O CMAQYLQZRJLQHR-UHFFFAOYSA-N 0.000 description 1
- ZSEFDNYXSJTSPU-UHFFFAOYSA-N 3-(4,4,4-trifluorobutylsulfonyl)phenol Chemical compound Oc1cccc(c1)S(=O)(=O)CCCC(F)(F)F ZSEFDNYXSJTSPU-UHFFFAOYSA-N 0.000 description 1
- INMJWEKOMZYPGS-UHFFFAOYSA-N 3-(cyclobutylmethylsulfonyl)phenol Chemical compound Oc1cccc(c1)S(=O)(=O)CC1CCC1 INMJWEKOMZYPGS-UHFFFAOYSA-N 0.000 description 1
- OARFLTDTKUTPNY-UHFFFAOYSA-N 3-(cyclohexylmethylsulfonyl)phenol Chemical compound OC1=CC=CC(S(=O)(=O)CC2CCCCC2)=C1 OARFLTDTKUTPNY-UHFFFAOYSA-N 0.000 description 1
- ZTNISUCKISMOHW-DMLGSKKGSA-N 3-[3-[[(2S)-oxiran-2-yl]methoxy]phenyl]sulfonylcyclobutan-1-ol Chemical compound OC1CC(C1)S(=O)(=O)c1cccc(OC[C@@H]2CO2)c1 ZTNISUCKISMOHW-DMLGSKKGSA-N 0.000 description 1
- XMHKIONBMYQDHL-LLVKDONJSA-N 3-[3-[[(2S)-oxiran-2-yl]methoxy]phenyl]sulfonylpropan-1-ol Chemical compound OCCCS(=O)(=O)c1cccc(OC[C@@H]2CO2)c1 XMHKIONBMYQDHL-LLVKDONJSA-N 0.000 description 1
- HRYRYDXLVUWWAA-SNVBAGLBSA-N 3-[3-[[(2S)-oxiran-2-yl]methoxy]phenyl]sulfonylpropanamide Chemical compound NC(=O)CCS(=O)(=O)c1cccc(OC[C@@H]2CO2)c1 HRYRYDXLVUWWAA-SNVBAGLBSA-N 0.000 description 1
- ULOVLVWNSQNABA-UHFFFAOYSA-N 3-amino-5-bromo-1h-pyridin-2-one Chemical compound NC1=CC(Br)=CNC1=O ULOVLVWNSQNABA-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- GNAVJIFADPVKDS-UHFFFAOYSA-N 3-benzylsulfonylphenol Chemical compound OC1=CC=CC(=C1)S(=O)(=O)CC1=CC=CC=C1 GNAVJIFADPVKDS-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- BSSKVXFGJJUKRR-UHFFFAOYSA-N 3-cyclobutylsulfonylphenol Chemical compound Oc1cccc(c1)S(=O)(=O)C1CCC1 BSSKVXFGJJUKRR-UHFFFAOYSA-N 0.000 description 1
- HODRCYVPYBGSNT-UHFFFAOYSA-N 3-cyclopentylsulfonylphenol Chemical compound C1(CCCC1)S(=O)(=O)C=1C=C(C=CC=1)O HODRCYVPYBGSNT-UHFFFAOYSA-N 0.000 description 1
- JHJKSEKUZNJKGO-UHFFFAOYSA-N 3-methoxybenzenesulfonyl chloride Chemical compound COC1=CC=CC(S(Cl)(=O)=O)=C1 JHJKSEKUZNJKGO-UHFFFAOYSA-N 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QTJFSBDKLGUYDE-BBMPLOMVSA-N 4-[3-[[3-[[(2S)-2-hydroxy-3-(3-methylsulfonylphenoxy)propyl]amino]-1-oxa-8-azaspiro[4.5]decan-8-yl]sulfonyl]phenyl]benzenesulfonamide Chemical compound CS(=O)(=O)C1=CC=CC(OC[C@@H](O)CNC2COC3(C2)CCN(CC3)S(=O)(=O)C2=CC=CC(=C2)C2=CC=C(C=C2)S(N)(=O)=O)=C1 QTJFSBDKLGUYDE-BBMPLOMVSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- OCVVGDZOPPMLIB-UHFFFAOYSA-N 4-methyl-2,3-dihydropyrido[3,2-b][1,4]oxazine-7-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CN=C2N(C)CCOC2=C1 OCVVGDZOPPMLIB-UHFFFAOYSA-N 0.000 description 1
- WWMRJCUZPJJWBC-UHFFFAOYSA-N 4-methyl-2-phenylpyridine Chemical compound CC1=CC=NC(C=2C=CC=CC=2)=C1 WWMRJCUZPJJWBC-UHFFFAOYSA-N 0.000 description 1
- KECCFSZFXLAGJS-UHFFFAOYSA-N 4-methylsulfonylphenol Chemical compound CS(=O)(=O)C1=CC=C(O)C=C1 KECCFSZFXLAGJS-UHFFFAOYSA-N 0.000 description 1
- JSWJLPOAQVOUQT-UHFFFAOYSA-N 4-oxo-1H-quinoline-3-sulfonyl chloride Chemical compound C1=CC=C2C(=O)C(S(=O)(=O)Cl)=CNC2=C1 JSWJLPOAQVOUQT-UHFFFAOYSA-N 0.000 description 1
- PCBJNDJWLHUDBE-UHFFFAOYSA-N 5,6,7,8-tetrahydroquinoline-3-sulfonyl chloride Chemical compound N1=CC(=CC=2CCCCC1=2)S(=O)(=O)Cl PCBJNDJWLHUDBE-UHFFFAOYSA-N 0.000 description 1
- BLJOCKNDWUTFEN-UHFFFAOYSA-N 5-bromo-2-chloro-4-methyl-3-nitropyridine Chemical compound CC1=C(Br)C=NC(Cl)=C1[N+]([O-])=O BLJOCKNDWUTFEN-UHFFFAOYSA-N 0.000 description 1
- BKWVCWSASGSHSS-UHFFFAOYSA-N 5-bromo-2-n-methylpyridine-2,3-diamine Chemical compound CNC1=NC=C(Br)C=C1N BKWVCWSASGSHSS-UHFFFAOYSA-N 0.000 description 1
- CZQZDTCBIKKGCI-UHFFFAOYSA-N 6-benzylsulfanyl-1H-pyrrolo[3,2-b]pyridine Chemical compound C(Sc1cnc2cc[nH]c2c1)c1ccccc1 CZQZDTCBIKKGCI-UHFFFAOYSA-N 0.000 description 1
- OJFFFCVPCVATIV-UHFFFAOYSA-N 6-bromo-1h-pyrrolo[3,2-b]pyridine Chemical compound BrC1=CN=C2C=CNC2=C1 OJFFFCVPCVATIV-UHFFFAOYSA-N 0.000 description 1
- IFIHYLCUKYCKRH-UHFFFAOYSA-N 6-bromoquinoline Chemical compound N1=CC=CC2=CC(Br)=CC=C21 IFIHYLCUKYCKRH-UHFFFAOYSA-N 0.000 description 1
- GAXXAYJLMCLODN-UHFFFAOYSA-N 6-fluoro-4-oxo-1H-quinoline-3-sulfonyl chloride Chemical compound Fc1ccc2[nH]cc(c(=O)c2c1)S(Cl)(=O)=O GAXXAYJLMCLODN-UHFFFAOYSA-N 0.000 description 1
- CNFSKTKKLJORIX-UHFFFAOYSA-N 6-methyl-4-oxo-1H-quinoline-3-sulfonyl chloride Chemical compound Cc1ccc2[nH]cc(c(=O)c2c1)S(Cl)(=O)=O CNFSKTKKLJORIX-UHFFFAOYSA-N 0.000 description 1
- PRJHEJGMSOBHTO-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-1-(3-hydroxypropyl)-3-methyl-8-[3-(trifluoromethoxy)phenoxy]purine-2,6-dione Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(CCCO)C(=O)N(C)C=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 PRJHEJGMSOBHTO-UHFFFAOYSA-N 0.000 description 1
- WRTGHVKSVDBNMZ-UHFFFAOYSA-N 7-bromo-1,3,3-trimethyl-2H-pyrido[2,3-b][1,4]oxazine Chemical compound BrC1=CC2=C(OC(CN2C)(C)C)N=C1 WRTGHVKSVDBNMZ-UHFFFAOYSA-N 0.000 description 1
- JZIGGNJBKKKOQF-UHFFFAOYSA-N 7-bromo-1,8-dimethyl-2,3-dihydropyrido[2,3-b][1,4]oxazine Chemical compound BrC1=C(C2=C(OCCN2C)N=C1)C JZIGGNJBKKKOQF-UHFFFAOYSA-N 0.000 description 1
- BACZEBIOBUIDHU-UHFFFAOYSA-N 7-bromo-1-(2-methoxyethyl)-2,3-dihydropyrido[2,3-b][1,4]oxazine Chemical compound BrC1=CC2=C(OCCN2CCOC)N=C1 BACZEBIOBUIDHU-UHFFFAOYSA-N 0.000 description 1
- VOMGFLFTSMFKGX-UHFFFAOYSA-N 7-bromo-1-methyl-2,3-dihydropyrido[2,3-b][1,4]oxazine Chemical compound C1=C(Br)C=C2N(C)CCOC2=N1 VOMGFLFTSMFKGX-UHFFFAOYSA-N 0.000 description 1
- VQHGKPGVAHEUQO-UHFFFAOYSA-N 7-bromo-1-methylspiro[2H-pyrido[2,3-b][1,4]oxazine-3,1'-cyclopropane] Chemical compound BrC1=CC2=C(OC3(CC3)CN2C)N=C1 VQHGKPGVAHEUQO-UHFFFAOYSA-N 0.000 description 1
- ZLHGUGJJHJJVHV-UHFFFAOYSA-N 7-fluoro-1h-quinolin-4-one Chemical compound N1C=CC(=O)C=2C1=CC(F)=CC=2 ZLHGUGJJHJJVHV-UHFFFAOYSA-N 0.000 description 1
- JPVTWKDGBWUNBQ-UHFFFAOYSA-N 7-methyl-1h-quinolin-4-one Chemical compound OC1=CC=NC2=CC(C)=CC=C21 JPVTWKDGBWUNBQ-UHFFFAOYSA-N 0.000 description 1
- IFWJUURJDVLJTL-UHFFFAOYSA-N 7-methyl-4-oxo-1H-quinoline-3-sulfonyl chloride Chemical compound OC1=C(C=NC2=CC(=CC=C12)C)S(=O)(=O)Cl IFWJUURJDVLJTL-UHFFFAOYSA-N 0.000 description 1
- NMOHQPRYBFUWQW-UHFFFAOYSA-N 8-fluoro-4-oxo-1H-quinoline-3-sulfonyl chloride Chemical compound FC=1C=CC=C2C(=C(C=NC=12)S(=O)(=O)Cl)O NMOHQPRYBFUWQW-UHFFFAOYSA-N 0.000 description 1
- HTISUYZVEWQIMP-UHFFFAOYSA-N 8-methyl-1h-quinolin-4-one Chemical compound C1=CN=C2C(C)=CC=CC2=C1O HTISUYZVEWQIMP-UHFFFAOYSA-N 0.000 description 1
- ATOIQMYFZPXJRF-UHFFFAOYSA-N 8-methyl-4-oxo-1H-quinoline-3-sulfonyl chloride Chemical compound OC1=C(C=NC2=C(C=CC=C12)C)S(=O)(=O)Cl ATOIQMYFZPXJRF-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- ALIKLAJJIYYMAW-UHFFFAOYSA-N B(Br)(Br)Br.[N] Chemical compound B(Br)(Br)Br.[N] ALIKLAJJIYYMAW-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- IOHHYPIOGCTBKP-UHFFFAOYSA-N C(C1=CC=CC=C1)SC=1C=C2C(=NC=1)C=CN2C(=O)OC(C)(C)C Chemical compound C(C1=CC=CC=C1)SC=1C=C2C(=NC=1)C=CN2C(=O)OC(C)(C)C IOHHYPIOGCTBKP-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- GTYHWPBAAGJMCG-UHFFFAOYSA-N ClS(=O)(=O)c1cnc2[nH]c(=O)[nH]c2c1 Chemical compound ClS(=O)(=O)c1cnc2[nH]c(=O)[nH]c2c1 GTYHWPBAAGJMCG-UHFFFAOYSA-N 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 1
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 1
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- MFESCIUQSIBMSM-UHFFFAOYSA-N I-BCP Chemical compound ClCCCBr MFESCIUQSIBMSM-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- UCMVGLKGEIINIF-UHFFFAOYSA-N N#CC(COF)(Cl)Br Chemical compound N#CC(COF)(Cl)Br UCMVGLKGEIINIF-UHFFFAOYSA-N 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- CMFAILDOLSALHK-UHFFFAOYSA-N N-[2-[4-(4-ethoxyphenyl)phenyl]ethyl]acetamide Chemical group C1=CC(OCC)=CC=C1C1=CC=C(CCNC(C)=O)C=C1 CMFAILDOLSALHK-UHFFFAOYSA-N 0.000 description 1
- IUYRJWZPHGWUTO-ACHIHNKUSA-N N-[2-[4-[3-[[(3S)-3-[[(2S)-2-hydroxy-3-[3-[1-(hydroxymethyl)cyclopropyl]sulfonylphenoxy]propyl]amino]-1-oxa-8-azaspiro[4.5]decan-8-yl]sulfonyl]phenyl]phenyl]ethyl]acetamide Chemical compound CC(=O)NCCC1=CC=C(C=C1)C1=CC(=CC=C1)S(=O)(=O)N1CCC2(C[C@@H](CO2)NC[C@H](O)COC2=CC(=CC=C2)S(=O)(=O)C2(CO)CC2)CC1 IUYRJWZPHGWUTO-ACHIHNKUSA-N 0.000 description 1
- QUEKOJKHCZSBFZ-LQJZCPKCSA-N N-[2-[4-[4-ethoxy-3-[[(3S)-3-[[(2S)-2-hydroxy-3-[3-[1-(hydroxymethyl)cyclopropyl]sulfonylphenoxy]propyl]amino]-1-oxa-8-azaspiro[4.5]decan-8-yl]sulfonyl]phenyl]phenyl]ethyl]acetamide Chemical compound C(C)OC1=C(C=C(C=C1)C1=CC=C(C=C1)CCNC(C)=O)S(=O)(=O)N1CCC2(C[C@@H](CO2)NC[C@@H](COC2=CC(=CC=C2)S(=O)(=O)C2(CC2)CO)O)CC1 QUEKOJKHCZSBFZ-LQJZCPKCSA-N 0.000 description 1
- QQGNLKJAIVSNCO-UHFFFAOYSA-N N-butylformamide Chemical compound CCCCNC=O QQGNLKJAIVSNCO-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 1
- 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 description 1
- JDQVWFFNCRNPEO-UHFFFAOYSA-N O1CC(CC11CCNCC1)C(CCOCCC(C1COC2(C1)CCNCC2)N)N Chemical class O1CC(CC11CCNCC1)C(CCOCCC(C1COC2(C1)CCNCC2)N)N JDQVWFFNCRNPEO-UHFFFAOYSA-N 0.000 description 1
- SZBJGRZNOYQTMZ-UHFFFAOYSA-N O1CC(CC11CCNCC1)N=[N+]=[N-] Chemical compound O1CC(CC11CCNCC1)N=[N+]=[N-] SZBJGRZNOYQTMZ-UHFFFAOYSA-N 0.000 description 1
- LUKYKLPDBIKGKO-UHFFFAOYSA-N O=S(C1=CNC2=CC=CC=C2C1)(Cl)=O.[O] Chemical compound O=S(C1=CNC2=CC=CC=C2C1)(Cl)=O.[O] LUKYKLPDBIKGKO-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000009982 Ventricular Dysfunction Diseases 0.000 description 1
- STZRMIALHYQQND-GFCCVEGCSA-N [1-[3-[[(2S)-oxiran-2-yl]methoxy]phenyl]sulfonylcyclobutyl]methanol Chemical compound O1[C@@H](C1)COC=1C=C(C=CC=1)S(=O)(=O)C1(CCC1)CO STZRMIALHYQQND-GFCCVEGCSA-N 0.000 description 1
- IVYFMPDKYCAFBA-LBAQZLPGSA-N [3-[[(2S)-2-hydroxy-3-(3-methylsulfonylphenoxy)propyl]amino]-1-oxa-8-azaspiro[4.5]decan-8-yl]-(1H-indol-2-yl)methanone Chemical compound O[C@@H](CNC1COC2(C1)CCN(CC2)C(=O)C=1NC2=CC=CC=C2C=1)COC1=CC(=CC=C1)S(=O)(=O)C IVYFMPDKYCAFBA-LBAQZLPGSA-N 0.000 description 1
- VOZSWVYTTQLAIL-ANYOKISRSA-N [3-[[(2S)-2-hydroxy-3-(3-methylsulfonylphenoxy)propyl]amino]-1-oxa-8-azaspiro[4.5]decan-8-yl]-(1H-indol-3-yl)methanone Chemical compound O[C@@H](CNC1COC2(C1)CCN(CC2)C(=O)C1=CNC2=CC=CC=C12)COC1=CC(=CC=C1)S(=O)(=O)C VOZSWVYTTQLAIL-ANYOKISRSA-N 0.000 description 1
- BPMDTOJNADUJGU-KEKNWZKVSA-N [3-[[(2S)-2-hydroxy-3-(3-methylsulfonylphenoxy)propyl]amino]-1-oxa-8-azaspiro[4.5]decan-8-yl]-(1H-indol-5-yl)methanone Chemical compound O[C@@H](CNC1COC2(C1)CCN(CC2)C(=O)C=1C=C2C=CNC2=CC=1)COC1=CC(=CC=C1)S(=O)(=O)C BPMDTOJNADUJGU-KEKNWZKVSA-N 0.000 description 1
- UTNQZZZXMAHMHR-KEKNWZKVSA-N [3-[[(2S)-2-hydroxy-3-(3-methylsulfonylphenoxy)propyl]amino]-1-oxa-8-azaspiro[4.5]decan-8-yl]-(1H-indol-6-yl)methanone Chemical compound O[C@@H](CNC1COC2(C1)CCN(CC2)C(=O)C1=CC=C2C=CNC2=C1)COC1=CC(=CC=C1)S(=O)(=O)C UTNQZZZXMAHMHR-KEKNWZKVSA-N 0.000 description 1
- VPNPSMMJHAYEBE-KEKNWZKVSA-N [3-[[(2S)-2-hydroxy-3-(3-methylsulfonylphenoxy)propyl]amino]-1-oxa-8-azaspiro[4.5]decan-8-yl]-(4-methyl-2,3-dihydro-1,4-benzoxazin-7-yl)methanone Chemical compound O[C@@H](CNC1COC2(C1)CCN(CC2)C(=O)C=1C=CC2=C(OCCN2C)C=1)COC1=CC(=CC=C1)S(=O)(=O)C VPNPSMMJHAYEBE-KEKNWZKVSA-N 0.000 description 1
- QPXSMHYBKCFEKW-UHFFFAOYSA-N [4-(4-propan-2-yloxyphenyl)phenyl]methanamine Chemical group C1=CC(OC(C)C)=CC=C1C1=CC=C(CN)C=C1 QPXSMHYBKCFEKW-UHFFFAOYSA-N 0.000 description 1
- XIPUIGPNIDKXJU-UHFFFAOYSA-N [CH]1CC1 Chemical compound [CH]1CC1 XIPUIGPNIDKXJU-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000009798 acute exacerbation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000005431 alkyl carboxamide group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 125000005418 aryl aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzenecarbonitrile Natural products N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000005872 benzooxazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- KHROHHIWLMXRBO-KRWDZBQOSA-N benzyl (3S)-3-[(2-methylpropan-2-yl)oxycarbonylamino]-1-oxa-8-azaspiro[4.5]decane-8-carboxylate Chemical compound C(C)(C)(C)OC(=O)N[C@@H]1COC2(C1)CCN(CC2)C(=O)OCC1=CC=CC=C1 KHROHHIWLMXRBO-KRWDZBQOSA-N 0.000 description 1
- HMOLUMBNXPQUPP-AWEZNQCLSA-N benzyl (3S)-3-amino-1-oxa-8-azaspiro[4.5]decane-8-carboxylate Chemical compound N[C@@H]1COC2(C1)CCN(CC2)C(=O)OCC1=CC=CC=C1 HMOLUMBNXPQUPP-AWEZNQCLSA-N 0.000 description 1
- KDXRCJKMAHBPSS-UHFFFAOYSA-N benzyl 2-ethylnonanoate Chemical compound CCCCCCCC(CC)C(=O)OCc1ccccc1 KDXRCJKMAHBPSS-UHFFFAOYSA-N 0.000 description 1
- IGMXTTSWLPFRAO-UHFFFAOYSA-N benzyl 3-azido-1-oxa-8-azaspiro[4.5]decane-8-carboxylate Chemical compound N(=[N+]=[N-])C1COC2(C1)CCN(CC2)C(=O)OCC1=CC=CC=C1 IGMXTTSWLPFRAO-UHFFFAOYSA-N 0.000 description 1
- YIFRDNMEJDKGSK-UHFFFAOYSA-N benzyl 3-hydroxy-1-oxa-8-azaspiro[4.5]decane-8-carboxylate Chemical compound OC1COC2(C1)CCN(CC2)C(=O)OCC1=CC=CC=C1 YIFRDNMEJDKGSK-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- VMGNXGOCEUEUER-UHFFFAOYSA-N benzyl spiro[4.5]decane-8-carboxylate Chemical compound C(C1=CC=CC=C1)OC(=O)C1CCC2(CCCC2)CC1 VMGNXGOCEUEUER-UHFFFAOYSA-N 0.000 description 1
- 102000016967 beta-1 Adrenergic Receptors Human genes 0.000 description 1
- 108010014494 beta-1 Adrenergic Receptors Proteins 0.000 description 1
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 description 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 125000006269 biphenyl-2-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C(*)C([H])=C([H])C([H])=C1[H] 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- LKXYJYDRLBPHRS-UHFFFAOYSA-N bromocyclopropane Chemical compound BrC1CC1 LKXYJYDRLBPHRS-UHFFFAOYSA-N 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 125000004775 chlorodifluoromethyl group Chemical group FC(F)(Cl)* 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- RUYNTLUDGSFPFZ-UHFFFAOYSA-N cyclobutanol Chemical compound OC1[CH]CC1 RUYNTLUDGSFPFZ-UHFFFAOYSA-N 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 150000001989 diazonium salts Chemical class 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical compound [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 description 1
- 229960005215 dichloroacetic acid Drugs 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000000597 dioxinyl group Chemical group 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229960001089 dobutamine Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- QMRUMRVXYYYILI-UHFFFAOYSA-N ethyl 1-(3-ethoxycarbonyloxyphenyl)sulfonylcyclopropane-1-carboxylate Chemical compound CCOC(=O)Oc1cccc(c1)S(=O)(=O)C1(CC1)C(=O)OCC QMRUMRVXYYYILI-UHFFFAOYSA-N 0.000 description 1
- JKHQMYNHTXJRMB-UHFFFAOYSA-N ethyl 1-(3-methoxyphenyl)sulfanylcyclobutane-1-carboxylate Chemical compound CCOC(=O)C1(CCC1)Sc1cccc(OC)c1 JKHQMYNHTXJRMB-UHFFFAOYSA-N 0.000 description 1
- HGLLJHRDMWKJSM-UHFFFAOYSA-N ethyl 1-(3-methoxyphenyl)sulfonylcyclobutane-1-carboxylate Chemical compound CCOC(=O)C1(CCC1)S(=O)(=O)c1cccc(OC)c1 HGLLJHRDMWKJSM-UHFFFAOYSA-N 0.000 description 1
- BAVVQLYHEBWLSM-UHFFFAOYSA-N ethyl 2,2-difluoro-2-(3-methoxyphenyl)sulfanylacetate Chemical compound FC(C(=O)OCC)(SC1=CC(=CC=C1)OC)F BAVVQLYHEBWLSM-UHFFFAOYSA-N 0.000 description 1
- YPZARUOOTBGGOG-UHFFFAOYSA-N ethyl 2,2-difluoro-2-(3-methoxyphenyl)sulfonylacetate Chemical compound FC(C(=O)OCC)(S(=O)(=O)C1=CC(=CC=C1)OC)F YPZARUOOTBGGOG-UHFFFAOYSA-N 0.000 description 1
- VMHPBZKVFYWNFR-UHFFFAOYSA-N ethyl 2-(3-hydroxyphenyl)sulfanyl-2-methylpropanoate Chemical compound CCOC(=O)C(C)(C)SC1=CC=CC(O)=C1 VMHPBZKVFYWNFR-UHFFFAOYSA-N 0.000 description 1
- IXUUUSYAPPAXJQ-UHFFFAOYSA-N ethyl 2-(3-hydroxyphenyl)sulfonyl-2-methylpropanoate Chemical compound OC=1C=C(C=CC=1)S(=O)(=O)C(C(=O)OCC)(C)C IXUUUSYAPPAXJQ-UHFFFAOYSA-N 0.000 description 1
- UCFVHXYCXZXDHV-UHFFFAOYSA-N ethyl 2-(5-bromo-4-methyl-3-nitropyridin-2-yl)oxyacetate Chemical compound BrC=1C(=C(C(=NC=1)OCC(=O)OCC)[N+](=O)[O-])C UCFVHXYCXZXDHV-UHFFFAOYSA-N 0.000 description 1
- IRSJDVYTJUCXRV-UHFFFAOYSA-N ethyl 2-bromo-2,2-difluoroacetate Chemical compound CCOC(=O)C(F)(F)Br IRSJDVYTJUCXRV-UHFFFAOYSA-N 0.000 description 1
- IOLQWGVDEFWYNP-UHFFFAOYSA-N ethyl 2-bromo-2-methylpropanoate Chemical compound CCOC(=O)C(C)(C)Br IOLQWGVDEFWYNP-UHFFFAOYSA-N 0.000 description 1
- ZANNOFHADGWOLI-UHFFFAOYSA-N ethyl 2-hydroxyacetate Chemical compound CCOC(=O)CO ZANNOFHADGWOLI-UHFFFAOYSA-N 0.000 description 1
- CMGCTCSFZMSGBJ-GFCCVEGCSA-N ethyl 2-methyl-2-[3-[[(2S)-oxiran-2-yl]methoxy]phenyl]sulfonylpropanoate Chemical compound CCOC(=O)C(C)(C)S(=O)(=O)c1cccc(OC[C@@H]2CO2)c1 CMGCTCSFZMSGBJ-GFCCVEGCSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- LDDOSDVZPSGLFZ-UHFFFAOYSA-N ethyl cyclopropanecarboxylate Chemical compound CCOC(=O)C1CC1 LDDOSDVZPSGLFZ-UHFFFAOYSA-N 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 125000005241 heteroarylamino group Chemical group 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 229960000443 hydrochloric acid Drugs 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000005945 imidazopyridyl group Chemical group 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 239000004041 inotropic agent Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- WHXMKTBCFHIYNQ-SECBINFHSA-N levosimendan Chemical compound C[C@@H]1CC(=O)NN=C1C1=CC=C(NN=C(C#N)C#N)C=C1 WHXMKTBCFHIYNQ-SECBINFHSA-N 0.000 description 1
- 229960000692 levosimendan Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000002514 liquid chromatography mass spectrum Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- LPEKGGXMPWTOCB-VKHMYHEASA-N methyl (S)-lactate Chemical compound COC(=O)[C@H](C)O LPEKGGXMPWTOCB-VKHMYHEASA-N 0.000 description 1
- WTUJXJAGPOXEFS-UHFFFAOYSA-N methyl 1-(5-bromo-3-nitropyridin-2-yl)oxycyclopropane-1-carboxylate Chemical compound COC(=O)C1(CC1)OC1=NC=C(Br)C=C1[N+]([O-])=O WTUJXJAGPOXEFS-UHFFFAOYSA-N 0.000 description 1
- KPJWVJURYXOHOO-UHFFFAOYSA-N methyl 1-hydroxycyclopropane-1-carboxylate Chemical compound COC(=O)C1(O)CC1 KPJWVJURYXOHOO-UHFFFAOYSA-N 0.000 description 1
- SYAWGWYAEAHIKT-UHFFFAOYSA-N methyl 3-quinolin-6-ylsulfonylpropanoate Chemical compound N1=CC=CC2=CC(=CC=C12)S(=O)(=O)CCC(=O)OC SYAWGWYAEAHIKT-UHFFFAOYSA-N 0.000 description 1
- PKAHQJNJPDVTDP-UHFFFAOYSA-N methyl cyclopropanecarboxylate Chemical compound COC(=O)C1CC1 PKAHQJNJPDVTDP-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- XCTTVNSXEHWZBI-UHFFFAOYSA-N n-(2-methylpropyl)formamide Chemical compound CC(C)CNC=O XCTTVNSXEHWZBI-UHFFFAOYSA-N 0.000 description 1
- XAYAMHJQZMRSLF-UHFFFAOYSA-N n-[(4-phenylphenyl)methyl]propan-2-amine Chemical group C1=CC(CNC(C)C)=CC=C1C1=CC=CC=C1 XAYAMHJQZMRSLF-UHFFFAOYSA-N 0.000 description 1
- KERBAAIBDHEFDD-UHFFFAOYSA-N n-ethylformamide Chemical compound CCNC=O KERBAAIBDHEFDD-UHFFFAOYSA-N 0.000 description 1
- KVTGAKFJRLBHLU-UHFFFAOYSA-N n-propan-2-ylformamide Chemical compound CC(C)NC=O KVTGAKFJRLBHLU-UHFFFAOYSA-N 0.000 description 1
- SUUDTPGCUKBECW-UHFFFAOYSA-N n-propylformamide Chemical compound CCCNC=O SUUDTPGCUKBECW-UHFFFAOYSA-N 0.000 description 1
- SDLAKRCBYGZJRW-UHFFFAOYSA-N n-tert-butylformamide Chemical compound CC(C)(C)NC=O SDLAKRCBYGZJRW-UHFFFAOYSA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- IPWFJLQDVFKJDU-UHFFFAOYSA-N pentanamide Chemical compound CCCCC(N)=O IPWFJLQDVFKJDU-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- FKRCODPIKNYEAC-UHFFFAOYSA-N propionic acid ethyl ester Natural products CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 1
- 125000006308 propyl amino group Chemical group 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- CDRNYKLYADJTMN-UHFFFAOYSA-N pyridine-3-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CN=C1 CDRNYKLYADJTMN-UHFFFAOYSA-N 0.000 description 1
- YBBBFMHGPCMHRZ-UHFFFAOYSA-N pyrido[2,3-b][1,4]oxazine Chemical compound C1=CC=C2[N]C=COC2=N1 YBBBFMHGPCMHRZ-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- HGKBSEQSLSSOLL-UHFFFAOYSA-N pyrrolo[1,2-a]pyrimidine-3-sulfonyl chloride Chemical compound ClS(=O)(=O)c1cnc2cccn2c1 HGKBSEQSLSSOLL-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 229940075993 receptor modulator Drugs 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- YICFALDKKMHFLT-UHFFFAOYSA-M sodium;3-methoxy-3-oxopropane-1-sulfinate Chemical compound [Na+].COC(=O)CCS([O-])=O YICFALDKKMHFLT-UHFFFAOYSA-M 0.000 description 1
- CAKRNZFEHKYKLV-UHFFFAOYSA-M sodium;3-methoxybenzenesulfinate Chemical compound [Na+].COC1=CC=CC(S([O-])=O)=C1 CAKRNZFEHKYKLV-UHFFFAOYSA-M 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000035458 subtype of a disease Diseases 0.000 description 1
- UDYFLDICVHJSOY-UHFFFAOYSA-N sulfur trioxide-pyridine complex Substances O=S(=O)=O.C1=CC=NC=C1 UDYFLDICVHJSOY-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- KCNXWZJEYVEGHN-UHFFFAOYSA-N tert-butyl 3-(3-hydroxyphenyl)sulfonylazetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(C1)S(=O)(=O)c1cccc(O)c1 KCNXWZJEYVEGHN-UHFFFAOYSA-N 0.000 description 1
- VINVFQZCCAOBBV-UHFFFAOYSA-N tert-butyl 6-chlorosulfonylpyrrolo[3,2-b]pyridine-1-carboxylate Chemical compound CC(C)(C)OC(=O)n1ccc2ncc(cc12)S(Cl)(=O)=O VINVFQZCCAOBBV-UHFFFAOYSA-N 0.000 description 1
- BUZXDESLJXFSCY-UHFFFAOYSA-N tert-butyl 7-chlorosulfonyl-2,3-dihydropyrido[2,3-b][1,4]oxazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCOc2ncc(cc12)S(Cl)(=O)=O BUZXDESLJXFSCY-UHFFFAOYSA-N 0.000 description 1
- VHSNQDZKERYICF-UHFFFAOYSA-N tert-butyl N-[2-(3-hydroxyphenyl)sulfonylethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCS(=O)(=O)c1cccc(O)c1 VHSNQDZKERYICF-UHFFFAOYSA-N 0.000 description 1
- FDDRUXJMZZXZKQ-UHFFFAOYSA-N tert-butyl N-decan-3-ylcarbamate Chemical compound CCCCCCCC(CC)NC(=O)OC(C)(C)C FDDRUXJMZZXZKQ-UHFFFAOYSA-N 0.000 description 1
- 125000006318 tert-butyl amino group Chemical group [H]N(*)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000583 toxicological profile Toxicity 0.000 description 1
- 239000006211 transdermal dosage form Substances 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 230000006815 ventricular dysfunction Effects 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662346293P | 2016-06-06 | 2016-06-06 | |
| US62/346,293 | 2016-06-06 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202237619A TW202237619A (zh) | 2022-10-01 |
| TWI784840B true TWI784840B (zh) | 2022-11-21 |
Family
ID=59067920
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110147004A TWI784840B (zh) | 2016-06-06 | 2017-06-06 | 用於治療或預防與β-3腎上腺素受體相關病症之β-3腎上腺素受體調節劑 |
| TW106118610A TWI752963B (zh) | 2016-06-06 | 2017-06-06 | 用於治療或預防與β-3腎上腺素受體相關病症之β-3腎上腺素受體調節劑 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW106118610A TWI752963B (zh) | 2016-06-06 | 2017-06-06 | 用於治療或預防與β-3腎上腺素受體相關病症之β-3腎上腺素受體調節劑 |
Country Status (29)
| Country | Link |
|---|---|
| US (5) | US20190284200A1 (OSRAM) |
| EP (1) | EP3464292B8 (OSRAM) |
| JP (3) | JP6771246B2 (OSRAM) |
| KR (2) | KR102408272B1 (OSRAM) |
| CN (1) | CN109563103B (OSRAM) |
| AR (1) | AR108772A1 (OSRAM) |
| AU (2) | AU2017278102B2 (OSRAM) |
| CA (1) | CA3026024C (OSRAM) |
| CL (1) | CL2018003451A1 (OSRAM) |
| CO (1) | CO2019000041A2 (OSRAM) |
| CR (1) | CR20180595A (OSRAM) |
| DK (1) | DK3464292T3 (OSRAM) |
| EA (1) | EA201892817A1 (OSRAM) |
| EC (1) | ECSP19001018A (OSRAM) |
| ES (1) | ES2929737T3 (OSRAM) |
| IL (2) | IL289378B (OSRAM) |
| MA (2) | MA44037B1 (OSRAM) |
| MX (2) | MX387995B (OSRAM) |
| MY (1) | MY195982A (OSRAM) |
| NI (1) | NI201800130A (OSRAM) |
| NZ (1) | NZ749202A (OSRAM) |
| PE (1) | PE20190445A1 (OSRAM) |
| PH (1) | PH12018502550B1 (OSRAM) |
| PT (1) | PT3464292T (OSRAM) |
| SG (1) | SG11201810788QA (OSRAM) |
| TN (1) | TN2018000391A1 (OSRAM) |
| TW (2) | TWI784840B (OSRAM) |
| UA (1) | UA125120C2 (OSRAM) |
| WO (1) | WO2017214002A1 (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA44037B1 (fr) * | 2016-06-06 | 2020-03-31 | Arena Pharm Inc | Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci |
| TN2019000290A1 (en) | 2017-03-20 | 2021-05-07 | Forma Therapeutics Inc | Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators |
| TWI822713B (zh) * | 2017-12-06 | 2023-11-21 | 美商艾尼納製藥公司 | 適用於治療或預防與其相關之病症之β－３腎上腺素受體的調節劑 |
| BR112021005188A2 (pt) | 2018-09-19 | 2021-06-08 | Forma Therapeutics, Inc. | tratamento de anemia falciforme com um composto de ativação de piruvato cinase r |
| JP7450610B2 (ja) | 2018-09-19 | 2024-03-15 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | ピルビン酸キナーゼｒの活性化 |
| BR112022004715A2 (pt) | 2019-09-19 | 2022-06-14 | Forma Therapeutics Inc | Composições de ativação de piruvato quinase r (pkr) |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| WO2023017388A1 (en) * | 2021-08-09 | 2023-02-16 | Arena Pharmaceuticals, Inc. | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure |
| CA3230339A1 (en) * | 2021-08-26 | 2023-03-02 | Arena Pharmaceuticals, Inc. | Modulators of the beta-3 adrenergic receptor for the treatment or prevention of renal cystic disease and cardiorenal syndrome |
| US20240409548A1 (en) * | 2021-10-06 | 2024-12-12 | Arena Pharmaceuticals, Inc. | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto |
| JP2025506667A (ja) * | 2022-02-14 | 2025-03-13 | バイオジェン・エムエイ・インコーポレイテッド | エモパミル結合タンパク質阻害剤及びその使用 |
| CN114539103B (zh) * | 2022-03-21 | 2023-04-07 | 佳木斯黑龙农药有限公司 | 2-二氟乙氧基-6-三氟甲基苯磺酰氯的合成方法 |
| CN116178220A (zh) * | 2022-12-13 | 2023-05-30 | 爱斯特（成都）生物制药股份有限公司 | 一种制备(2s)-2-[[3-(甲基磺酰基l)苯氧基]甲基]环氧乙烷的方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001043744A1 (fr) * | 1999-12-17 | 2001-06-21 | Sanofi-Synthelabo | Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant |
| TW200533351A (en) * | 2004-03-23 | 2005-10-16 | Pfizer | Compounds for the treatment of diseases |
| WO2010058318A1 (en) * | 2008-11-21 | 2010-05-27 | Pfizer Inc. | 1-oxa-8-azaspiro [4, 5 ] decane- 8 -carboxamide compounds as faah inhibitors |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3028340C2 (de) * | 1980-07-25 | 1987-02-05 | Dr. Willmar Schwabe GmbH & Co, 7500 Karlsruhe | Amino-desoxy-1.4;3.6-dianhydro-hexit-nitrate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen |
| US5254595A (en) | 1988-12-23 | 1993-10-19 | Elf Sanofi | Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them |
| FR2751646B1 (fr) | 1996-07-23 | 1999-01-22 | Sanofi Sa | Phenoxypropanolamine a action antagoniste beta3-adrenergique |
| WO1998027080A1 (en) | 1996-12-19 | 1998-06-25 | Agrevo Uk Limited | Chromones useful as fungicides |
| FR2780057B1 (fr) * | 1998-06-18 | 2002-09-13 | Sanofi Sa | Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant |
| DE20204129U1 (de) | 2002-03-15 | 2002-07-25 | Wella Ag, 64295 Darmstadt | Mittel zur Färbung von Keratinfasern mit Chinolinium-Farbstoffen |
| EP1833480A2 (en) * | 2004-11-30 | 2007-09-19 | Artesian Therapeutics, Inc. | Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase |
| US8697674B2 (en) | 2004-12-29 | 2014-04-15 | Naturon, Inc. | Xanthurenic acid derivative pharmaceutical compositions and methods related thereto |
| WO2008094507A2 (en) | 2007-01-26 | 2008-08-07 | Cellicon Biotechnologies, Inc. | Novel fusion compounds |
| US8039505B2 (en) | 2007-04-11 | 2011-10-18 | University Of Utah Research Foundation | Compounds for modulating T-cells |
| WO2009059225A2 (en) | 2007-11-02 | 2009-05-07 | Pain Therapeutics, Inc. | Analgesia with minimal tolerance and dependence by a mu opioid receptor agonist that also binds filamin a |
| EP2488177B1 (en) | 2008-10-31 | 2016-10-12 | Pain Therapeutics, Inc. | Filamin a binding anti-inflammatory and analgesic |
| AU2009308769B2 (en) | 2008-10-31 | 2015-03-12 | Pain Therapeutics, Inc. | Filamin A-binding anti-inflammatory analgesic |
| US20100279997A1 (en) | 2009-05-04 | 2010-11-04 | Lindsay Burns Barbier | Analgesic that binds filamin a |
| US8785634B2 (en) * | 2010-04-26 | 2014-07-22 | Merck Sharp & Dohme Corp | Spiropiperidine prolylcarboxypeptidase inhibitors |
| EP2595483B1 (en) * | 2010-07-23 | 2017-03-22 | Merck Sharp & Dohme Corp. | Novel pyrrolidine derived beta 3 adrenergic receptor agonists |
| JP2012092038A (ja) | 2010-10-26 | 2012-05-17 | F Hoffmann La Roche Ag | 糖尿病、糖尿病関連疾患又は糖尿病性合併症の予防又は治療剤 |
| DK2882428T3 (en) | 2012-07-13 | 2019-04-15 | Pain Therapeutics Inc | PROCEDURE TO INHIBIT TAU PHOSPHORIZATION |
| EP2872899B1 (en) | 2012-07-13 | 2018-07-11 | Pain Therapeutics, Inc. | Alzheimer's disease assay in a living patient |
| GB201405359D0 (en) | 2014-03-25 | 2014-05-07 | Univ Liverpool | Synthetic process |
| MA44037B1 (fr) | 2016-06-06 | 2020-03-31 | Arena Pharm Inc | Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci |
| TWI822713B (zh) * | 2017-12-06 | 2023-11-21 | 美商艾尼納製藥公司 | 適用於治療或預防與其相關之病症之β－３腎上腺素受體的調節劑 |
-
2017
- 2017-06-04 MA MA44037A patent/MA44037B1/fr unknown
- 2017-06-05 MX MX2018015124A patent/MX387995B/es unknown
- 2017-06-05 DK DK17730638.8T patent/DK3464292T3/da active
- 2017-06-05 AU AU2017278102A patent/AU2017278102B2/en active Active
- 2017-06-05 SG SG11201810788QA patent/SG11201810788QA/en unknown
- 2017-06-05 MY MYPI2018002257A patent/MY195982A/en unknown
- 2017-06-05 TN TNP/2018/000391A patent/TN2018000391A1/en unknown
- 2017-06-05 US US16/307,830 patent/US20190284200A1/en not_active Abandoned
- 2017-06-05 WO PCT/US2017/035867 patent/WO2017214002A1/en not_active Ceased
- 2017-06-05 EA EA201892817A patent/EA201892817A1/ru unknown
- 2017-06-05 PE PE2018003180A patent/PE20190445A1/es unknown
- 2017-06-05 PT PT177306388T patent/PT3464292T/pt unknown
- 2017-06-05 KR KR1020227004041A patent/KR102408272B1/ko active Active
- 2017-06-05 NZ NZ749202A patent/NZ749202A/en not_active IP Right Cessation
- 2017-06-05 UA UAA201900139A patent/UA125120C2/uk unknown
- 2017-06-05 CA CA3026024A patent/CA3026024C/en active Active
- 2017-06-05 PH PH1/2018/502550A patent/PH12018502550B1/en unknown
- 2017-06-05 JP JP2019516084A patent/JP6771246B2/ja active Active
- 2017-06-05 MA MA045150A patent/MA45150A/fr unknown
- 2017-06-05 KR KR1020197000005A patent/KR20190026731A/ko not_active Withdrawn
- 2017-06-05 ES ES17730638T patent/ES2929737T3/es active Active
- 2017-06-05 CR CR20180595A patent/CR20180595A/es unknown
- 2017-06-05 IL IL289378A patent/IL289378B/en unknown
- 2017-06-05 EP EP17730638.8A patent/EP3464292B8/en active Active
- 2017-06-05 CN CN201780047870.6A patent/CN109563103B/zh active Active
- 2017-06-06 TW TW110147004A patent/TWI784840B/zh active
- 2017-06-06 AR ARP170101546A patent/AR108772A1/es active IP Right Grant
- 2017-06-06 TW TW106118610A patent/TWI752963B/zh active
-
2018
- 2018-11-20 IL IL263148A patent/IL263148B/en unknown
- 2018-12-03 CL CL2018003451A patent/CL2018003451A1/es unknown
- 2018-12-05 NI NI201800130A patent/NI201800130A/es unknown
- 2018-12-05 MX MX2021014043A patent/MX2021014043A/es unknown
-
2019
- 2019-01-04 CO CONC2019/0000041A patent/CO2019000041A2/es unknown
- 2019-01-07 EC ECSENADI20191018A patent/ECSP19001018A/es unknown
- 2019-06-04 US US16/431,209 patent/US10479797B2/en active Active
- 2019-09-06 US US16/563,353 patent/US10662200B2/en active Active
-
2020
- 2020-05-12 US US16/872,812 patent/US10927123B2/en active Active
- 2020-09-18 JP JP2020157196A patent/JP7083087B2/ja active Active
- 2020-12-14 US US17/120,759 patent/US11560386B2/en active Active
-
2021
- 2021-07-20 AU AU2021206809A patent/AU2021206809B2/en active Active
-
2022
- 2022-04-21 JP JP2022069821A patent/JP7449329B2/ja active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001043744A1 (fr) * | 1999-12-17 | 2001-06-21 | Sanofi-Synthelabo | Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant |
| TW200533351A (en) * | 2004-03-23 | 2005-10-16 | Pfizer | Compounds for the treatment of diseases |
| WO2010058318A1 (en) * | 2008-11-21 | 2010-05-27 | Pfizer Inc. | 1-oxa-8-azaspiro [4, 5 ] decane- 8 -carboxamide compounds as faah inhibitors |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI784840B (zh) | 用於治療或預防與β-3腎上腺素受體相關病症之β-3腎上腺素受體調節劑 | |
| US11987588B2 (en) | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | |
| HK40004811A (en) | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto | |
| HK40004811B (en) | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto | |
| EA041181B1 (ru) | Модулятор бета-3-адренергического рецептора, применяемый для лечения или предотвращения связанных с данным рецептором расстройств | |
| BR112018075201B1 (pt) | Compostos moduladores do receptor beta-3 adrenérgico e composição farmacêutica que os compreende, seus usos e método de preparação da referida composição | |
| HK40006318B (en) | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto | |
| HK40006318A (en) | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto | |
| HK40039344A (en) | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | |
| HK40039344B (en) | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto |